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Abstract 
 
Epilepsy is one of the most common neurological disorders and affects millions of people 
in the United States. Currently available antiepileptic drugs require continuous 
administration for suppression of seizures and have not been shown to prevent the 
development of epilepsy (epileptogenesis). The discovery of antiepileptogenic drug is 
complicated by the long time course of epileptogenesis in animal models of epilepsy and 
the requirement of continuous monitoring of epileptiform activity in vivo for the 
assessment of drug efficacy. In recent years, organotypic hippocampal cultures have been 
increasingly used as an in vitro model of post-traumatic epilepsy in both basic and 
translational research. Epileptogenesis in this in vitro model has a compressed time scale 
and can be monitored by detection of electrographic and biochemical markers of seizure-
like activity. However, the lack of a scalable chronic electrical recording platform is a 
significant bottleneck in high-throughput antiepileptogenic drug discovery using 
organotypic cultures.        
In an effort to circumvent the throughput limitations of in vitro antiepileptogenic drug 
discovery, a hybrid microfluidic-multiple electrode array (µflow-MEA) technology was 
developed for scalable chronic electrical assay of epileptogenesis in vitro. Specifically, the 
microfluidic perfusion technique was utilized to miniature the culture platform, which 
enabled the long-term maintenance of an organotypic culture array on a single device. The 
integration of the microfluidic perfusion system with a customized planar MEA allowed 
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for parallel continuous recordings. As a proof-of-concept demonstration, a pilot screen of 
receptor tyrosine kinase (RTK) inhibitor library was performed on µflow-MEA based 
electrical assay platform. The screen results revealed significant antiepileptogenic effect of 
cFMS RTK inhibitor. 
This thesis also provides further validation of the organotypic hippocampal culture model 
of epilepsy by investigating the influence of culture medium composition on 
epileptogenesis. We found that epileptogenesis occurred in any culture medium that was 
capable of supporting neural survival, indicating that culture medium composition has 
limited influence on epileptogenesis in organotypic hippocampal cultures. 
It is hoped that the techniques presented in this thesis will accelerate the antiepileptogenic 
drug discovery and contribute to the development of new therapeutics to treat individuals 
at risk of epileptogenesis. 
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Chapter 1 
Introduction 
 
 
1.1 In vitro model of epileptogenesis and drug discovery 
Epilepsy affects around 50 million people worldwide, making it one of the most common 
neurological disorders [1]. Diverse acquired brain insults, including traumatic brain injury, 
stroke, infections, and tumors [2,3], can introduce epileptogenesis, a process by which 
normal brain is transformed into epileptic brain generating spontaneous recurrent seizures. 
Epileptogenesis includes (1) a latent period between brain insults and the onset of seizure, 
and (2) the progression of epilepsy after it is established [4] (Figure 1.1). The latent period 
may vary from months to years in patients [5–7], presenting a window of opportunity for 
therapies that aim to prevent or delay the development of epilepsy [8]. Alternatively, 
treatments may be administered after the seizure onset to modify the progression of 
epilepsy, by reducing or eliminating seizures permanently. These therapies are defined as 
having an effect of antiepileptogensis [4]. Currently available antiepileptic drugs (AEDs) 
are anticonvulsants that require continuous administration for suppression of seizures, and 
they have not been shown to prevent epileptogenesis [9–11]. Furthermore, approximately 
30% of patients are drug refractory [12]. At present, epileptogenesis is not a treatment 
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indication, and there is no therapy available in clinic to treat individuals at risk of 
epileptogenesis. Therefore, discovery of antiepileptogenic interventions that prevent, 
interrupt or reverse epileptogenesis has been identified as an epilepsy research benchmark 
[13,14].  
 
Figure 1.1 Definition of epileptogenesis. Epileptogenesis includes the latent period, 
which is defined as the time between brain insults and the occurrence of the first 
unprovoked seizure, and extends beyond the latent period, when seizure frequency and 
severity progressively increase over time. Reproduced with permission from [4].  
 
Development of antiepileptogenic drugs is complicated by the long latent period which 
varies from weeks to months in epileptic animal models [15–17]. Antiepileptogenic effects, 
including (1) delays in seizure onset, alterations in seizure probability versus time after 
injury, and (2) reductions in seizure frequency, intensity, and duration, can occur over 
timescales of days to weeks after compounds application. Thus, continuous 
electroencephalogram (EEG) monitoring of electrographic seizures is necessary for 
sensitive and quantitative assessment of drug efficacy [2,3], which requires time-
consuming and expensive surgical procedures for electrode implantation in animals models. 
Difficulty and high-cost of long-term continuous recording result in a low experimental 
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throughput, presenting a practical challenge for antiepileptogenic drug development. 
Limited throughput is also a major factor that prevents the use of small molecule panels in 
a target-independent approach for antiepileptogenic drug discovery. One promising option 
to circumvent these problems is to use in vitro preparations of epileptogenesis [18]. 
As an in vitro alternative to animal models, brain slices are extensively used for 
toxicological and pharmacological profiling, or carrying out candidate compound screens 
to discover new drugs against neurological diseases [19–24]. Especially, hippocampal 
slices are increasingly used as an in vitro model of traumatic brain injury-induced epilepsy, 
or post traumatic epilepsy [25–28]. Organotypic brain slice cultures were developed to 
maintain slice viability for weeks and months [29]. Since the cultures maintain the 
cytoarchitecture of the originating brain regions, they are termed organotypic slice cultures 
(Figure 1.2A), and these cultures are often used as models for studies on long term 
neurological processes, such as neurogenesis [30], synaptic plasticity [31], and 
epileptogenesis [25,28,32]. The time scale of epileptogenesis in organotypic hippocampal 
slice cultures (1-2 weeks) is much faster than in animal models, and more amenable to 
high-throughput analysis (Figure 1.2B). This model captures critical features of 
epileptogenesis, including the latent period between trauma and the appearance of 
spontaneous epileptiform activity, seizure-dependent cell death, and responses to 
anticonvulsants [28,33] (Figure 1.2C). Epileptogenesis in this model can be monitored with 
chronic imaging, electrical recording, or by detecting biochemical markers of seizures 
[28,33,34].  Organotypic cultures thus provide an easy-to-access in vitro model for 
antiepileptic drug discovery [33–38]. The organotypic hippocampal culture based 
“epilepsy-in-a-dish” model was first developed in 2010, when Dyhrfjeld-Johnsen et al. 
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provided detailed characterizations of the development and evolution of epileptiform 
activity within this in vitro model of chronic epilepsy [32]. In 2012, Berdichevsky et al. 
further characterized the features of this model, like activity-dependent cell death, response 
to anticonvulsants, and emergence of anticonvulsant resistance [28]. After that, the 
organotypic hippocampal slice culture was proposed as an in vitro disease model for 
screening of anticonvulsants and antiepileptogenic therapies, which identified the 
cyclooxygenase inhibitor, Celecoxib, as a novel anticonvulsant and mTOR as an effective 
target of epileptogenesis [33,38]. 
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Figure 1.2 Post traumatic epilepsy is modeled in organotypic hippocampal cultures. 
(A) Left, hippocampus anatomy in rodent brain. Middle, brightfield image of organotypic 
hippocampal culture after 14 days in vitro (DIV). Scale bar, 500 µm. Right, confocal 
imaging of NeuN staining in CA1 and CA3 regions show densely packed neurons. Scale 
bars, 50 µm. (B) Representative recordings on different DIV, revealing the time course of 
epileptogenesis in organotypic hippocampal cultures. (C) Electrographic responses to 
known anticonvulsant. Left, electrical recording reveals that seizures stopped during 
phenytoin application. Right, these results were typical (n = 6, each group). Reproduced 
with permission from [28].  
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High-throughput drug screens based on the organotypic hippocampal culture model will 
require massively parallel recordings for over two weeks for the observation of 
epileptogenesis. However, traditional methods of maintaining organotypic cultures, 
interface methods [29] and roller-tube methods [39], are not directly compatible with 
electrophysiology platforms for chronic recording or scalable to support high-throughput 
electrical assays [40] (Figure 1.3A, B). The lack of a scalable chronic electrical recording 
system is a significant bottleneck for antiepileptogenic drug discovery using organotypic 
cultures.  
 
Figure 1.3 Conventional and microfluidic perfusion methods to maintain brain slices. 
Interface methods (A) and roller-tube methods (B) to maintain organotypic brain slice 
cultures. (C) Microfluidic perfusion system for brain slice that can highly miniaturize the 
culture platform and provide versatile designs. Reproduced with permission from [40].  
 
The rapid progress of technologies for microfluidics and biological 
microelectromechanical systems (BioMEMS) over the past decade has enabled the 
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development of simplified, microengineered platforms that are highly amenable to 
miniaturization, high-throughput experimentations, and real-time analysis for in vitro 
neurobiological studies [40,41], providing an avenue to address the throughput limitations 
in organotypic culture based drug discovery. 
 
1.2 Microfluidic-MEA technology for brain slice based study 
Neural activity within a volume of brain tissue gives rise to transmembrane currents, 
including synaptic activity, action potentials, Ca2+ spikes, and intrinsic currents and 
resonances [42]. All ionic processes superimpose in space to yield field potentials (FPs) 
that can be measured in the extracellular medium. Synaptic transmembrane currents are the 
major contributors to FPs [42]. When neuron receives a synaptic input, the generated 
transmembrane current gives rise to a current sink, where currents flow from the 
extracellular into the intracellular space, and a current source, where currents flow from 
the intracellular to the extracellular space, along the neuron. Depending on the locations of 
sink and source, a current dipole or higher order n-pole is formed, giving rise to the FPs 
(Figure 1.4A). Unlike intracellular recording techniques that use sharp or patch 
microelectrodes to detect activity of individual neurons, extracellular recording of FPs with 
metal microelectrodes is able to detect both single and multiple neuron activity, and it is 
therefore more applicable to network level analysis of population activity in neuronal 
networks, like sharp wave-ripples and epilepsy [43] (Figure 1.4B).  
Multiple microelectrodes can be integrated on a planar surface to create multiple electrode 
arrays (MEAs), a technique adopted from the microelectronics industry [44,45]. When 
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fabricating an MEA chip, the selection of materials depends on the type of experiment that 
will be conducted: dissociated neuron, acute brain slices, or organotypic cultures. Some 
factors to be considered are: biocompatibility, optical transparency, and insulation 
durability. The most commonly used material for the substrate is glass, which can be easily 
interfaced with optical microscopy. Gold, platinum, titanium nitride, and indium-tin oxide 
are used for conductor patterns, including electrodes, track, and contact pads. In the case 
of gold and platinum, an additional metal layer such as titanium or chromium is required 
to promote the adhesion between the glass substrate and metal. The standard fabrication 
process includes conductor patterning, insulator coating and electrode opening (Figure 
1.4C). The conductor layer is deposited onto the substrate using sputtering, thermal 
evaporation or e-beam evaporation. The desired pattern is defined by photolithography 
followed by a wet or dry etching process. To prevent signal crosstalk and dissipation, an 
insulation layer is required to passivate conductor tracks. Normally used isolation types are: 
Silicon dioxide, silicon nitride, SU-8, polyimide, and Polydimethylsiloxane (PDMS). 
Following the insulation, the layout of electrodes and contact pads are exposed by 
photolithography and etching (depending on the material). Dozens of microelectrodes on 
MEA chip enable multiple-sites recordings with high spatial resolution, which is crucial 
for studies of network activities, like signal processing and neurotransmission. Importantly, 
a planar MEA provides a noninvasive neural-electrode interface that allows for long-term 
recording and stimulation.    
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Figure 1.4 Multiple electrode array (MEA) for extracellular electrophysiology. (A-B) 
The origin of extracellular field potentials (FPs). Reproduced with permission from [42]. 
(A) A current sink-source dipole is induced by inhibitory synaptic input at the perisomatic 
region (red symbol). Lines represent isopotentials (red, positive; blue, negative). FPs are 
recorded from 6 sites at vicinity of the neuron. Electrodes are shown in yellow. (B) FPs 
recorded from different sites in hippocampus during synchronized sharp wave activity 
(traces shown in grey). Current sink-source distribution is shown in color map. (C) 
Standard MEA fabrication process.  
 
Using MEAs to record epileptiform activity in brain slices gives rise to novel epilepsy-on-
a-chip systems [46–49]. Hill et al. used MEAs to record burst activities in an acute 
hippocampal slice model of status epilepticus. Multiple-sites recordings were used to 
assess burst propagation speed and frequency as novel parameters for anticonvulsants 
screening [46]. To investigate the modulatory effect of thalamic inputs on seizures 
generated in anterior cingulate cortex (ACC), Chang et al. used MEA recordings to study 
spatiotemporal properties of epileptiform activity in acute thalamic-ACC slice [47]. Hsiao 
et al. reported MEA recordings from different subregions of human epileptic hippocampal 
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slice to study epilepsy generation and propagation in hippocampal circuitry [48]. Ferrea et 
al. developed a large-scale array recording simultaneously from 4096 electrodes to study 
propagating epileptiform activity in acute murine cortico-hippocampal brain slices, and 
topologically localized and quantified the effects of antiepileptic drugs in local neuronal 
microcircuits [49].   
It is important to note that planar MEA chips are compatible with organotypic culture 
methods and have been used to chronically record spontaneous activity in cortical and 
hippocampal cultures over several weeks [50–57]. To study the formation and stabilization 
of axonal projections, Hofmann et al. kept organotypic co-culture of entorhinal cortex (EC) 
and dentate gyrus (DG) slice on an MEA chip for up to 6 weeks (Figure 1.5A). The progress 
of neurite outgrowth and the establishment of functional connections were evaluated by 
analyzing the correlation of evoked signals in EC and DG after electrical stimulation in EC 
[54]. Gong et al. developed a high-density MEA to record electrical activity of individual 
neurons at a high spatial resolution, while monitoring neuronal network activity 
simultaneously in an organotypic hippocampal slice for 4 weeks [55]. A recently developed 
integrated device combined interstitial perfusion and perforated MEA to optimize nutrient 
and oxygen diffusion and enable long-term maintenance of organotypic cultures [56]. 
MEAs can provide immensely parallel recording for high-throughput electrical assay of 
epileptogenesis in vitro. However, currently available MEA chips, for example 
Multichannel Systems, MED64, and Qwane Biosciences, are designed to support only one 
slice culture. The primary factor limiting the number of cultures that can be placed on a 
MEA chip is that traditional culture methods consume large areas of MEA real estate, thus 
preventing high-throughput on-chip experimentations.  
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Figure 1.5 MEA device supports long-term recordings in organotypic culture. (A) 
Organotypic co-culture of entorhinal cortex (EC) and dentate gyrus (DG) maintained on 
MEA chip and evoked signals recorded by MEA electrodes. Reproduced with permission 
from [54]. (B) Microfluidic compartment integrated MEA device supports organotypic 
hippocampal culture and electrophysiology for 4 weeks. Reproduced with permission from 
[58]. 
 
Microfluidics has been previously used to pattern dissociated-neuron based model systems 
[59–62] and to perfuse brain slices [40]. Several groups have reported successful 
integration of microchannel patterns and MEAs with precise alignment between fluidic and 
electronic device components for neural-electrical interfaces [63,64,58,65]. 
Kanagasabapathi et al. bonded compartmented neuron co-culture system to MEAs to study 
the propagation of neural activities between cortical and thalamic neurons [63]. Dworak et 
al. integrated MEAs with PDMS microtunnels to study in vitro neuronal communication. 
In this device, axons extended through the narrow microchannels, and highly selective 
recordings of axonal signals were acquired by MEAs underneath [64]. To investigate the 
information processing in neural networks, Scott et al. developed a microfluidic MEA 
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device with the capability to allow simultaneous multi-sites extracellular recording, and 
focal chemical stimuli delivered by microfluidic network [65]. Berdichevsky et al. used a 
PDMS mini-well to maintain organotypic hippocampal slice cultures on MEA surface for 
4 weeks, and microchannels were incorporated into the mini-well to guide the axons 
sprouting [58] (Figure 1.5B). Microfluidic perfusion can be introduced to miniaturize the 
brain slice culture platform, by removing medium storage off-device and provide versatile 
designs [40] (Figure 1.3C). Furthermore, perfused brain slices may more closely resemble 
their in situ counterparts that are highly perfused by vascular networks in vivo [66–68]. 
However, most microfluidic perfusion systems are used in acute brain slice based studies, 
and relatively little attention has been paid to using microfluidic technology to improve the 
throughput of organotypic culture based experiments.  
A novel MEA chip that is integrated with scalable microfluidic perfusion system, which 
enables long-term parallel recordings from multiple organotypic cultures in a single device, 
will make it possible for high-throughput electrical assay for antiepileptogenic drug 
discovery in vitro. 
 
1.3 Cell signaling pathways in epilepsy 
Some of the characteristics of the epileptic brain include axon sprouting, synaptic 
reorganization, inflammation, and hyperexcitability [2,3,8]. These processes are regulated 
by kinase signaling pathways [8,69–76]. Furthermore, the human genome includes over 
500 kinase genes [77], and many of them play important roles in cellular processes in the 
nervous system [78]. It is highly possible that they are involved in epileptogenesis. Small 
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molecular inhibitors have been synthesized for many of these kinases and are used 
extensively in cancer research. Inhibition of these pathways has the potential to prevent 
formation of epileptic circuitry and thus prevent epileptogenesis after brain injury, or even 
disrupt existing epileptic circuits and cure epilepsy. Some kinase signaling pathways, 
including the PI3k-Akt-mTOR, JAK-STAT, and BDNF-TrkB pathways, have been 
implicated in animal and in vitro models of acquired chronic epilepsies [33,75,79–84]. 
However, only a small percentage of the total kinome have been explored as potential 
targets for antiepileptogenic drugs. For example, many receptor tyrosine kinases (RTKs) 
are expressed in the brain and have been reported to respond to brain injury [85–94], but 
only a few of them have been investigated for inhibition of epileptogenesis. Interestingly, 
the TrkB receptor and the Insulin-like Growth Factor-I Receptor (two types of RTKs) have 
been implicated in epileptogenesis [82–84,95,96]. Other pathways, including JAK-STAT 
and Wnt signaling, which have strong cross-talk with RTK, have also been found to play a 
role in epilepsy [97–99]. This evidence suggests that the RTK signaling network plays a 
prominent role in epileptogenesis and may provide potential targets for antiepileptogenic 
drugs. However, the RTK signaling network is highly complex. There are over 20 RTKs 
expressed in the hippocampus and cortex at significant levels (based on Allen Brain Atlas 
mouse data), and the downstream signaling have cross-talk with multiple other pathways 
[100], which makes the matrix of experiments very large.  
This thesis will focus on the development of an organotypic hippocampal culture based 
screen platform for systematic investigation of the role of cell signaling pathways in 
epileptogenesis, which may have a transformative impact on the search for better therapies 
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for epilepsy. A pilot screen of RTK inhibitor library will be described as a demonstration 
of  how this platform provides rapid dissection of signaling pathways in epilepsy.  
 
1.4 Goals of this thesis 
The general aim of the work described in this thesis is to develop a hybrid microfluidic-
MEA (µflow-MEA) technology for scalable chronic electrical assay of epileptogenesis in 
vitro and to demonstrate how µflow-MEA facilitates antiepileptogenic drug discovery. The 
specific objectives are:       
1. To develop a scalable microfluidic perfusion system for long-term maintenance of 
organotypic hippocampal cultures (Chapter 2) [101].  
2. To integrate microfluidic perfusion system with MEAs for scalable chronic electrical 
assay of epileptogenesis and carry out a pilot screen of a small-molecule kinase (RTK) 
inhibitor library (Chapter 3).  
3. To validate the organotypic hippocampal culture model of epilepsy by studying the 
influence of culture medium composition on epileptogenesis (Chapter 4) [102].  
Finally, future work of this research is discussed (Chapter 5).   
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Chapter 2 
Development of microfluidic perfusion culture platform  
 
              
 
2.1 Motivation 
Both perfusion and electrophysiology are highly amenable to miniaturization, and a 
number of groups reported microfluidic perfusion devices and multiple electrode array 
chips (MEAs) designed specifically for brain slices. Major goals of microfluidic device 
development were to precisely control slice microenvironment [1], enhance nutrient and 
oxygen supply [2–4], or improve experimental access to the slice [5] (see [6] for a 
comprehensive review).  MEA development focused on capturing spatiotemporal patterns 
of neural activity by increasing the number of electrodes per slice [7,8], recording from 
neurons deep within the slice [9], or improving viability of the slice on electrode array chip 
[10]. These efforts may be summarized as applications of microtechnology to improve the 
fidelity of brain slice experiments.  
On the other hand, relatively little attention has been paid to using microtechnology to 
improve the throughput of brain slice experiments, especially the long-term experiments 
The work described in this section has been published in “Perfused drop 
microfluidic device for brain slice culture-based drug discovery” by Liu 
J, Pan L, Cheng X, Berdichevsky Y, Biomed Microdevices. 2016;18: 46. 
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that require electrical recordings of organotypic cultures for multiple days or weeks. Brain 
slice based drug screens typically rely on simple interface or submerged-type perfusion 
and only one or two electrodes per slice for stimulation or recording. However, a screen of 
a compound library may require hundreds or thousands of well-controlled experiments 
with replicates. Multi-slice systems have been developed to allow simultaneous, 
independent electrophysiological recordings from multiple brain slices [11–13]. However, 
these systems require the use of multiple perfusion systems, machined slice chambers and 
discrete micromanipulator-mounted electrodes, imposing practical limitations on the 
number of parallel experiments. Slice survival in these multiple-slice systems is limited to 
only 7 hours, precluding long-term experiments on organotypic cultures [12].   
We set out to apply microtechnology to increase the throughput of organotypic 
hippocampal culture based antiepileptogenic drug screening. Techniques for maintaining 
organotypic brain slice cultures for multiple weeks have been developed over 20 years ago 
(methods and applications of brain slice cultures are reviewed in [14]).  In an interface 
method, the slice is placed on a porous membrane, and culture medium is added so that the 
slice is located at an air-medium interface [15].  In a roller-tube method, the slice is attached 
to a glass cover slip with a blood clot or collagen gel. The slip is then placed into a tube 
with culture medium that is rotated on a roller drum at a slow speed, bringing the slice in 
and out of medium [16]. Both methods ensure that the slice is directly exposed to 
atmospheric oxygen (100% of the time with the interface method, and approximately 50% 
of the time with the roller-tube method) to ensure viability in vitro for multiple weeks. 
Since slices maintain the cytoarchitecture of the originating brain regions, they are termed 
organotypic slice cultures. However, neither interface nor roller-tube methods of producing 
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organotypic cultures are directly compatible with microfluidics. A more recently 
developed method is based on maintaining a slice in a culture medium-filled well cut in a 
polydimethylsiloxane (PDMS) film [17]. The well is connected with a larger medium 
reservoir via channels in PDMS film. Glass culture substrate can be easily substituted for 
a glass-based MEA to enable continuous electrical recording of neural activity in the slice. 
A disadvantage of this method is the requirement for a large medium reservoir that takes 
up valuable MEA area and limits the number of cultures that can be placed on a single 
MEA chip.  Another limitation is the lack of a perfusion system for applying drugs or other 
compounds to slices.   
In this work we developed a novel perfused drop technique to enable the placement of 
multiple organotypic cultures on a single microfluidic device. This scalable culture 
platform is compatible with MEA and capable of significantly increasing the throughput 
of organotypic culture experiments on chip. In our design, hippocampal slice are 
maintained in individual drops confined by PDMS wells. The drops are continuously 
perfused with fresh culture medium through microchannels. PDMS microfluidic network 
can be easily integrated with a planar MEA chip for chronic recordings. The device requires 
only 3 cm2 area per culture, potentially enabling experiments with up to 6 cultures per 
single 2”x 2” MEA chip. A single integrated device may potentially replace an entire 
system for parallel electrophysiology in multiple organotypic hippocampal cultures, 
enabling scalable electrical assay of epileptogenesis in vitro.  
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2.2 Device design and theory 
In our design, slice culture is maintained on a glass substrate in a PDMS culture well with 
lithographically defined microchannel as the medium flow inlet and an open channel as the 
outlet (Figure 2.1). The microchannel is connected to a feeding syringe tube placed at a 
specific height to provide proper medium flow rate. The outlet is connected to a reservoir 
where waste medium is removed by a vacuum needle. Culture well is open for optimal 
oxygen diffusion to the cultures (similar to interface method for organotypic cultures) and 
to provide culture medium surface tension to push the slices against culture substrate for 
better tissue attachment.  
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Figure 2.1 Perfused drop organotypic slice culture platform. (A) Schematic of the 
system setup. PDMS device consists of a membrane (110 µm thick) with an inlet 
microchannel (20 µm high, 50 µm wide), an open outlet channel (0.5 mm wide) and a 
culture well (3 mm radius), as well as a PDMS tubing stand and reservoir (2 mm thick). 
Gravity provides the input culture medium flow through microchannel. Output flow goes 
to reservoir through open channel and is collected by a vacuum needle. Top view (B) and 
3D view (C) of a single device layout. (D) Schematic and photograph of a triple slice device 
filled with dye solution. Overall device size is 3 cm × 3 cm. 
 
In the absence of flow, size of the drop in the culture well and fluid level in the reservoir 
are balanced by surface tension and gravity. Adjustment of fluid height in the reservoir  𝐻1 
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changes the drop size in the culture well (Figure 2.2). Since drop in the culture well is not 
strictly symmetrical due to the presence of an open outlet channel, we describe it by left 
contact angle 𝛽𝑙 (closest to reservoir) and the right contact angle 𝛽𝑟 (closest to inlet), and 
their average 𝛽. We built a simple static model consisting of several force components.  In 
the reservoir, there is pressure due to gravity 𝑃1, and pressure due to capillary force 𝑃2; in 
culture well, there is also pressure due to gravity 𝑃3, and pressure due to surface tension 𝑃4. 
In the absence of flow, 
𝑃2 − 𝑃1 = 𝑃4 − 𝑃3      (1) 
𝑃1 = 𝜌𝑔𝐻1    (2)     𝑃2 = 2𝛾𝑐𝑜𝑠𝛼 (
1
𝑤
+
1
ℎ
)    (3)      𝑃3 = 𝜌𝑔𝐻2    (4)      𝑃4 =
2𝛾𝑐𝑜𝑠𝛽
𝑅
    (5) 
where 𝜌 is the density of fluid, 𝑔 is gravity acceleration, 𝛾 is surface tension of fluid, 𝛼 is 
the contact angle in the reservoir,  𝑤 is the width of the reservoir, ℎ is the length of the 
reservoir, H1 is fluid height in the reservoir, 𝐻2 is fluid height in the culture well, 𝑅 is the 
radius of the culture well, 𝑧1 is the height of the reservoir, and 𝑧2 is the height of the culture 
well.  𝐻2 can be described in terms of contact angle 𝛽： 
𝐻2 = 𝑧2 −
𝑅
𝑐𝑜𝑠𝛽
(1 − 𝑠𝑖𝑛𝛽)      (6) 
cos𝛼 can be described in terms of 𝐻1: 
𝑐𝑜𝑠𝛼 = −
𝑤(𝐻1 − 𝑧1)
(
𝑤
2)
2
+ (𝐻1 − 𝑧1)2
         (7) 
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We can then express the average contact angle 𝛽 of the culture drop in terms of fluid height 
𝐻1 in the reservoir: 
2𝛾𝑐𝑜𝑠𝛽
𝑅
− 𝜌𝑔 (𝑧2 −
𝑅
𝑐𝑜𝑠𝛽
(1 − 𝑠𝑖𝑛𝛽)) = −
2𝛾𝑤(𝐻1 − 𝑧1)
(
𝑤
2)
2 + (𝐻1 − 𝑧1)2
(
1
𝑤
+
1
ℎ
) − 𝜌𝑔𝐻1      (8) 
Solving Navier-Stokes equation gives the velocity profile for a pressure-driven, steady-
state flow in a microchannel of rectangular cross section. The flow rate 𝑄 can be found by 
integrating flow velocity in the inlet channel of width 𝑊 and height 𝐻. For a channel with 
aspect ratio 𝑎 < 1 (𝑎 = 𝐻/𝑊), flow rate can be approximated by [18]: 
𝑄 ≈
𝐻4∆𝑝
12𝜂𝐿𝑎
(1 − 0.63𝑎)       (9) 
where 𝜂 is the viscosity of fluid, 𝐿 is the length of microchannel, and ∆𝑝 is the pressure 
difference between two ends of the microchannel, in this case, the gravity pressure due to 
feeding syringe: 
∆𝑝 = 𝜌𝑔𝑍    (10) 
𝑍 is the height difference between the fluid level in the feeding syringe and the device.  
 39 
 
 
Figure 2.2 Device in the absence of flow. (A) Photograph of the dye-filled device with no 
input flow. (B) Different levels of fluid in the reservoir control the shape of the culture well 
drop. BSA solution contains red dye, while water is colored with blue dye. (C) 
Experimental measurements and analytical solution of 𝛽 versus 𝐻1  for BSA solution (2.5 
g/L) and water.  Correlation coefficient 𝑅2 is 0.78 for water and 0.83 for BSA solution; p 
<0.001 for both fluids. 
 
2.3 Experimental methods 
2.3.1 Device fabrication 
Culture compartments were fabricated from PDMS. Silicon mold masters were prepared 
by defining a microchannel pattern via SU-8 (Microchem) photolithography on a 3" silicon 
wafer. A pattern of 20 µm height and 50 µm width was fabricated. Liquid PDMS was spin-
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coated onto the silicon master at 600 rpm for 1 min, and cured at 75 °C for at least 4 h. The 
resulting 110 µm PDMS film with imprinted microchannels was removed from the silicon 
wafer. Culture wells of 6 mm diameter and the open channels of 0.5 mm × 8 mm were cut 
in the PDMS membrane. Fluid inlets of 0.025 mm diameter were created by puncturing the 
PDMS membrane with a syringe needle. The length of inlet microchannel L (edge to edge 
distance between fluid input to the device and culture well) is 6 mm (Figure 2.1). PDMS 
compartments were attached to glass substrate through oxygen plasma bonding. Then 2 
mm thick PDMS reservoir (5 mm × 25 mm inner area) and input tubing stand (5 mm × 5 
mm) were bonded to PDMS membrane. Tubing stand through-hole (0.1 mm diameter) was 
centered on the punctured fluid inlet. The edge to edge distance between reservoir and 
culture well is 4 mm. Devices were autoclaved for sterilization. Then each device was 
placed in a 100 mm petri dish, and incubated in humidified atmosphere at 37 °C overnight, 
with culture wells coated with poly-D-lysine (PDL, Sigma).  Devices were then washed in 
three changes of sterile distilled water, and incubated for at least 3 hours with culture wells 
covered with NeurobasalA/B27 medium (Invitrogen) before culturing.  
2.3.2 Velocity modeling 
Flow in the culture well was simulated using COMSOL-Multiphysics. Geometry of the 
simulated chamber mimicked the ones used for the experiments. A plug flow of 0.01 m/s 
was applied at the inlet of the microchannel leading to the slice chamber. The velocity was 
calculated as the preset flow rate of 1 mL/day divide by the cross section area of the 
microchannel (20 µm x 50 µm). The fluid surface exposed to air was set as an open 
boundary and the air phase was neglected, considering the low viscosity of air compared 
to water. All the other boundaries were set as no-slip boundaries.  Brain tissue in the culture 
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well was represented by a solid cylindroid located at the center with a semi-major axis of 
1.2 mm, semi-minor axis of 1 mm and height of 0.2 mm. Fluid parameters corresponding 
to water were used in the simulation. 
2.3.3 Organotypic cultures 
Hippocampi were dissected from postnatal day 7-8 Sprague-Dawley rat pups (Charles 
River Laboratories), cut into 350 µm slices on a McIlwain tissue chopper (Mickle 
Laboratory Eng. Co., Surrey, United Kingdom). Slices were placed in the culture wells of 
the microfluidic devices, and controls were placed onto PDL coated 6-well tissue culture 
plates. All cultures were maintained in serum-free NeurobasalA/B27 medium containing 
0.5 mM glutaMAX (Invitrogen) and 30 mg/L gentamicin (Invitrogen) and incubated at 
37 °C in 5% CO2.  Control slices placed in 6-well culture plate were placed on a rocking 
platform. Medium was changed twice a week. Slices within microfluidic perfusion devices 
were gravity-fed from a syringe tube with a loose-fitting cap, and the flow rate was set to 
approximately 1 ml/day per culture by placing the feeding syringe at a height of 20 cm. 
Fluid was split by a 1 to 6 mini-manifold (Warner Instruments) to supply 2 triple 
microfluidic perfusion devices. The fluid level in the feeding syringe was checked daily 
and replenished every day to maintain same height Z. The feeding tubing was 0.030" ID, 
0.065" OD ultra-purity white silicone tubing (Mcmaster-Carr). Polyethylene tubing with 
0.023" ID, 0.038" OD (Warner Instruments) was used as the interconnector of feeding 
tubing to mini-manifold, and feeding tubing to PDMS tubing stand. Manifolds and tubing 
were sterilized by autoclaving, except for polyethylene tubing which was sterilized by 
ethanol.  All animal use protocols were approved by the Institution Animal Care and Use 
Committee (IACUC) at Lehigh University and were conducted in accordance with the 
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United States Public Health Service Policy on Humane Care and Use of Laboratory 
Animals. 
2.3.4 Immunohistochemistry 
NeuN antibody is a marker for neurons that specifically recognizes DNA-binding, neuron-
specific protein NeuN, which is present in most CNS and PNS neuronal cell types. Cultures 
were washed in phosphate-buffered saline (PBS), and fixed for 2 h in 4% 
paraformaldehyde. Cultures were then transferred to 48-well petri dish, and permeabilized 
in 0.3% Triton X-100 (Sigma-Aldrich) in PBS for 2 h, then blocked with 10% goat serum 
in PBS for 1 h, followed by incubation for 24 h in 1% NeuN at +4 °C on a shaker.  Slices 
were then washed and mounted for confocal microscopy. Z-stack images were collected 
on confocal microscope (Zeiss LSM 510 META, Germany) with 5x and 40x objectives. Z-
stack layers were separated by 2 µm, and depth ranged from 40 µm-60 µm.  Images were 
then processed in Fiji [19].  Neuron numbers were quantified per single field of view of 
high-magnification images, in the optical slice with maximum number of neurons in CA1 
and CA3 areas of control and perfused-drop cultures.  
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2.4 Results and discussion 
2.4.1 Static analysis 
Devices were evaluated under static (no flow) conditions with bovine serum albumin (BSA) 
solution (2.5 g/L), which mimics the surface tension of culture medium, and distilled water. 
We increased the fluid volume in the reservoir to increase the fluid level in the culture well 
(Figure 2.2B).  Averages of 3 separate measurements of 𝐻1 , 𝛽𝑙  and 𝛽𝑟  for each fluid 
volume were calculated for three different devices and plotted in Figure 2.2C.  Results were 
compared to formula (8), evaluated with average dimensions of 3 different devices: 𝑧1 = 
1.7 mm, 𝑤 = 5.8 mm, ℎ = 25.8 mm, 𝑅 = 3 mm, and 𝑧2 = 110 µm, 𝜌 = 10
3 kg/m3. Surface 
tension values of distilled water and BSA solution (2.5g/L) at 37 °C were 70 mN/m and 54 
mN/m, respectively [20,21].  Analytical solutions of 𝛽  dependence on 𝐻1  for BSA-
containing solution and water were plotted in Figure 2.2C. A good fit with the experimental 
data for water and BSA solution was observed. Correlation coefficients between 
experimental and theoretical values were 𝑅2 = 0.78 for water, and 𝑅2 = 0.83 for BSA 
solution; 𝑝 <0.001 for both fluids.  
In the static model (Figure 2.2), we only consider the operation range of 1 mm < 𝐻1< 4 
mm because values of  𝐻1 less than 1mm reduce 𝛽 below 90 degrees. This may lead to 
cultures drying out.  Fluid confinement by hydrophobic PDMS surface fails for 𝐻1> 4mm, 
imposing an upper limit to the range of 𝐻1. The open channel connecting culture well and 
reservoir may also contribute to fluid balance. However, considering that its area is less 
than 10% of the culture well area, its surface tension may be ignored. In Figure 2.2C, 
theoretical curves of water and BSA solution are close to each other signifying that 
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difference in surface tensions between these two fluids does not strongly affect operation 
of our device.  This is also supported by lack of difference between experimental data for 
water and BSA. 
2.4.2 Dynamic analysis 
𝑍 was set to 20 cm in subsequent culture experiments. 𝛽𝑙 and 𝛽𝑟 were measured while the 
drop in culture well was perfused with BSA solution, and compared to static values 
obtained from the same device without perfusion (Figure 2.3A, B).  The introduction of 
flow had no significant influence on the geometry of drop in culture well (for 𝛽𝑙, p = 0.911; 
for 𝛽𝑟, p = 0.760; n=3, paired t test).  While fluid flow introduces pressure changes inside 
the culture well, the highest pressure change is at the fluid inlet (approximately 0.01 Pa, 
from COMSOL simulation), was less than 0.015% of the pressure in no-flow condition 
(𝑃3 − 𝑃4 is approximately 70 Pa).  Therefore, the shape of the drop in culture well is largely 
determined by static forces. 
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Figure 2.3 Dynamic modeling of streamline and velocity profile in the perfused drop 
device. (A) Photograph of the device under static condition (left, flow was stopped by 
switch) and dynamic condition (right, there is continuous input flow). 𝐻1, 𝛽𝑙 and 𝛽𝑟 were 
measured in these two conditions on 3 devices. (B) Comparison of 𝛽𝑙 and 𝛽𝑟 under static 
condition and dynamic conditions. ● represents no flow, and ○ represents continuous flow. 
(C) Streamlines of the velocity field. Circle in the center of the culture well represents brain 
slice. Flow enters the culture well from the microchannel on the left, flows around the 
culture and then leaves through the open channel on the right. (D) Velocity magnitude 
distribution inside the culture well. High velocity appears at the inlet and outlet but 
decreases quickly closer to the brain slice. (The simulation results refer to the horizontal 
plane at the microchannel midpoint). 
 
We then determined if Eq. (9) accurately models the flow rate in our device.  We used the 
following values: 𝐻 = 20 µm, 𝑎 = 0.4, 𝑍 = 20 cm, and 𝐿 = 6 mm. Viscosity of water is 𝜂 = 
0.71×10-3 Pa·s at 37 °C [22]. Viscosity of BSA solution is approximately the same since 
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low concentration of BSA used in culture medium does not significantly alter fluid 
viscosity [23]. The calculated flow rate 𝑄 was 42 µl/h, which is approximately 1 ml/day 
per slice. In culturing experiments approximately 1 ml/day of culture medium was used 
per slice, which matches with the calculated flow rate.  
Increase of flow rate improves the oxygen/nutrient delivery [24]. However, the 
correspondingly increased fluid velocity can cause larger shear forces that have the 
potential to damage tissues [25].  In our platform, the flow rate is set at 1 ml/day. For slices 
cultured in standard 6-well plate, the medium consumption rate is about 0.3 ml/day [26]. 
Thus, our perfused drop device is characterized by a comparatively high perfusate 
exchange rate which may lead to improved culture viability. COMSOL simulation of the 
streamline and velocity profile 10 µm above the substrate (microchannel midpoint) are 
shown in Figure 2.3C, D. A relatively high velocity above 0.01 m/s only occur near the 
inlet and outlet. The maximum velocity of 0.018 m/s occurs at the outlet of the 
microchannel, and decreases rapidly after entering the culture well. As demonstrated in 
Figure 2.3D, velocity is in the range of 5-20 × 10-6 m/s in the vicinity of cultured slice, 
indicating that slice experiences relatively little shear stress.   
2.4.3 Culture viability 
𝐻1 was set to 1.5 mm to make 𝛽 approximately 100 degrees. This was found to be the 
optimum drop shape for culture viability, since drops with larger 𝛽 caused slices to detach, 
while drops with smaller 𝛽 caused slices to dry out. The culture viability was evaluated at 
5 DIV and 9 DIV by brightfield microscope imaging and confocal imaging of NeuN stained 
organotypic hippocampal cultures (Figure 2.4). Compared with control cultures, perfused 
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drop cultures showed similar well maintained cytoarchitecture with clearly defined neural 
layers. Neuron counts on 9 DIV were not different between control and perfusion slices in 
CA1 (p = 0.599, student t test, n = 3 each condition), but perfusion cultures had 
significantly higher number of neurons than control cultures in CA3 (p = 0.036, student t 
test, n = 3 each condition) (Figure 2.4C).The results showed that viable cultures could be 
maintained in microfluidic perfusion system for at least 9 DIV with no reduction in the 
number of neurons in the hippocampal pyramidal layers. 
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Figure 2.4 Morphology of organotypic hippocampal cultures maintained in the 
perfused drops. Morphology of control (interface method) cultures and perfused drop 
cultures were compared on 5 DIV (A) and 9 DIV (B) by brightfield and confocal imaging. 
Cultures were stained with NeuN for confocal imaging. Scale bars, 500 µm. (C) Higher 
magnification micrographs of NeuN staining in CA1 and CA3 regions show that similar 
numbers of neurons survived in control and perfused drop cultures. Scale bars, 50 µm. (D) 
Neuron counts in CA1 and CA3. n = 3 each condition. Error bars indicate SD, * p < 0.05. 
 
Our morphological findings show that perfused drop method enables organotypic cultures 
that are as viable as cultures maintained with roller-tube or interface methods.  Perfused 
drop method enables integration of organotypic cultures with MEA fabricated on any 
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PDMS-bondable substrate such as glass, without the need for specialty perforated MEA 
[10], thus potentially reducing the costs of organotypic culture-based drug discovery. 
Traditional methods of maintaining organotypic cultures require large area of culture 
substrate to hold the culture medium. In a 6 well plate, each slice takes up to ~10 cm2, 
while actual area of a hippocampal slice is only ~ 0.07 cm2. In our triple device (Figure 
2.1D), each slice takes up only 3 cm2 if reservoir area is taken into account.  The reduction 
in required area is achieved by moving the medium storage off the device.  Since more than 
three culture wells can share one reservoir, the amount of area required per cultured slice 
will become smaller with more slices per device. More cultures can be added by simply 
patterning more wells and microchannels in the PDMS film without an increase in the cost 
of the device. Thus, our perfused drop culture method is inherently scalable, and may 
replace entire systems [11–13] with a single integrated microfluidic-MEA chip. Another 
advantage of this platform is the transparent and planar design that enables convenient 
optical microscopy.  
 
2.5 Conclusions 
In this work, we developed a microfluidics-based method that highly increases the 
scalability of organotypic culture platform. Our method is compatible with planar MEA 
technology, and will enable parallel chronic electrical recordings of epileptogenesis in vitro. 
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Chapter 3 
µflow-MEA technology for antiepileptogenic drug 
discovery 
 
 
3.1 Motivation 
High-throughput drug screens based on organotypic culture model of epilepsy require 
massively parallel recordings for over two weeks for the observation of epileptogenesis. 
Multiple electrode array (MEA) technology provides the highly parallel recordings and 
supports chronic recordings in organotypic brain slice cultures over several weeks [1–8]. 
However, typical MEA devices are deigned to support only one brain slice culture, due to 
the low scalability of organotypic culture chamber. Here we describe a hybrid microfluidic-
MEA (µflow-MEA) technology that incorporates perfused drop technique [9] described in 
Chapter 2 and MEA based parallel electrophysiology into a miniaturized device for 
scalable electrical assays of epileptogenesis.  
In standard MEA designs, an insulation layer is required to confine the active area of 
electrodes in order to prevent signal dissipation and increase detection sensitivity. The most 
used isolation types are: Silicon dioxide, silicon nitride, and SU-8 [10–13]. Silicon dioxide 
and silicon nitride require chemical vapor deposition (CVD) and etching process for 
electrode opening. SU-8 layer is spin coated to the device, and then electrodes are exposed 
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by photolithography. This chapter will describe a simplification in the MEA design to 
detect electrographic seizures which are characterized by synchronized population activity. 
Computational simulation of field potential was conducted to verify the capability of this 
simplified MEA to achieve good detection of seizure-like activity.   
To demonstrate how this µflow-MEA technology can facilitate antiepileptogenic drug 
discovery, we conducted a pilot screen of small molecular inhibitors. In this work, we focus 
on the investigation of receptor tyrosine kinases (RTKs), a class of kinases that act as cell 
surface receptors. Many of RTKs are expressed in the hippocampus, and have been 
reported to respond to brain injury [14–20], the most common known cause of acquired 
epilepsy [21,22]. Therefore there is a significant likelihood that RTKs may play a role in 
epileptogenesis. Lactate and Lactate dehydrogenase (LDH) measurements have been used 
to evaluate antiepileptic drug efficacy in organotypic cultures [23–25], since their 
concentrations in the spent culture medium were found to be correlated with seizure-like 
activity and seizure-dependent cell death, respectively. Lactate and LDH productions can 
be measured by commercial assay kits, enabling rapid analysis of drug effects on 
epileptogenesis. Lactate level also depends on the number of surviving neurons in the 
culture since neurons produce physiological lactate even when there is no seizure. Thus, 
analysis of cell death via LDH assay is necessary to interpret lactate level as a marker of 
seizure-like activity. However, LDH assay cannot reflect the cell death when apoptotic 
cells degrade without releasing LDH into culture supernatant [26]. Candidate drugs might 
have unpredictable effects on cell survival, which would complicate the interpretation of 
lactate and LDH data. Furthermore, spent culture medium are sampled at twice-weekly 
medium changes for lactate and LDH assays. So that the lactate and LDH levels reflect the 
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overall seizure load in the 3-4 days period between medium changes, providing a 
measurement of seizure activity with low temporal resolution. In contrast, continuous 
electrical recordings provide direct measurement of electrographic seizures at high-
resolution. Therefore, for accurate assessment of drug efficacy, it is important to use 
chronic electrical assay to verify the lactate and LDH data, or even replace the lactate and 
LDH assays when high-throughput can be achieved. In this work, we present a two-stage 
screening platform based on organotypic hippocampal cultures model of epilepsy. The first 
stage was for biochemistry assays, where epileptogenesis was evaluated by measurements 
of lactate and LDH levels during chronic inhibitor application. The second stage was for 
µflow-MEA technology based chronic electrical assay to verify the results obtained in 
stage I.  
 
3.2 Experimental methods  
3.2.1 Device design and fabrication 
The µflow-MEA device was the integration of customized MEA chip with PDMS 
microfluidic perfusion compartments we developed in our previous work [9] described in 
Chapter 2. The device has 8 metal microelectrodes (30 µm × 3 mm) recording from 6 
culture wells, with one electrode for each well, and one additional electrode in two wells 
(since we used a 16 channel data acquisition system, 8 channels were allocated to each 
device), and a reference electrode (diameter = 3 mm) in the fluid reservoir (Figure 3.1). 
For the purpose of drug screening, we simplified the MEA design by excluding the 
isolation process to make the device cheap and quickly fabricated. PDMS microfluidic 
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system was bonded to metal patterned MEA chip as an insulator to passivate conductor 
tracks, and the recording electrodes were left uninsulated in the organotypic culture well.  
Glass slides (2 × 2 inch, Fisher Scientific) were cleaned in Piranha solution. The electrodes 
pattern was defined photolithographically with negative lift-off process using AZ nLOF 
2070 (MicroChem). Titanium (50 nm) and gold (200 nm) were deposited with e-beam 
evaporator to make the electrodes. The photoresist was lifted with photoresist stripper AZ 
400T (MicroChem) at 80 °C for 3 hours, leaving the electrode pattern on the glass slide. 
PDMS compartments were assembled to the MEA chip through oxygen plasma bonding, 
with electrodes centered in culture wells. MEA integrated device was then autoclaved for 
sterilization before culturing.  
 
Figure 3.1 Schematic representation of the µflow-MEA chip. This device is the 
integration of PDMS microfluidic perfusion system [9] and MEA printed glass substrate 
for long-term parallel recording in 6 organotypic hippocampal cultures. 
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3.2.2 Field potential simulation 
Field potentials were simulated using COMSOL-Multiphysics (COMSOL Inc.). The 3D 
geometry model included the culture well, current source model of seizure and 2D recoding 
electrodes. We built a simplified current source model based on the hippocampal slice 
geomerty to reflect seizure-like activity when the whole hippocampal network is 
synchronized. Insulating boundary conditions were assigned to the circumference and the 
floor of the culture well, and the air-medium interface. The conductivity of the medium 
was set as 1.5 S/m to match reported conductivity of artificial cerebrospinal fluid (aCSF) 
[27–29].  
3.2.3 Preparation of organotypic cultures 
For experiments in stage I, slices were maintained in 6-well tissue culture plates. For µflow 
perfused culture in stage II, slices were placed in the mini culture wells of µflow-MEA 
device and perfused at the rate of 1 ml/day per culture. Details are described in Chapter 2. 
3.2.4 Morphology Analysis  
Brightfield images were taken on an upright microscope (Olympus) with 4x objective. 
Cultures’ “health” was evaluated based on three morphological criteria: 1. Blurriness of 
the culture edge. Blurry edges indicate that the slice has attached well to the polylysine 
substrate, while distinct edge indicates that the slice has not integrated well with the 
substrate. Very unhealthy slices become completely detached and float in the culture media. 
2. Brightness of the slices. Unhealthy slices appear darker than healthy slices due to 
accumulation of cellular debris. 3. Integrity and distinctness of neural layers. Healthy slices 
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have well-preserved cytoarchitecture with distinct CA1, CA3 neural layers and dentate 
gyrus (DG). 
3.2.5 Drug application and assays 
Phenytoin was dissolved in dimethylsulfoxide (DMSO), and added to the culture medium 
at 100 μM concentration. Phenytoin was applied when consistent seizure-like activity was 
observed. Cultures were perfused by medium with phenytoin for 10 hours, then switched 
back to normal medium perfusion. Electrical recordings before, during and after drug 
perfusion were analyzed to evaluate the drug efficacy.  
Cultures from the same animal were organized into four experimental groups to test three 
drugs with a vehicle-treated control (n = 3 cultures each condition). All inhibitors were 
dissolved in DMSO and applied to cultures starting on 3 DIV. Control cultures were treated 
with 0.1% DMSO as vehicle. Toxicity pre-screen (0-7 DIV) was conducted by morphology 
analysis and measurement of LDH on 7 DIV. Cultures showed either unhealthy 
morphology or significantly higher LDH than control were deemed toxic and a lower 
concentration of applied drug was retested until the maximum nontoxic concentration was 
identified. The maximum nontoxic concentration of each drug were then applied in two 
stage chronic screens. In stage I, culture supernatant was collected on 3, 7, 10, 14, 17 and 
21 DIV and seizure-like activity and cell death were measured by lactate and LDH assay, 
respectively. Lactate and LDH concentrations in the supernatant were determined by using 
kits (Eton Bioscience and Roche Diagnostics, respectively) according to manufacturers’ 
protocols. Lactate concentrations were calculated relative to known lactate standards, while 
LDH concentrations were calculated in terms of arbitrary units (a.u.), normalized to the 0 
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- 3 days in vitro (DIV) average of LDH concentration in control culture supernatant. In 
stage II, cultures were perfused by culture medium with drugs from 3 DIV to 14 DIV. 
Chronic electrical recordings were then used to evaluate drug efficacy. 
3.2.6 Immunohistochemistry 
NeuN staining refers to Chapter 2. Slices were then washed and mounted for confocal 
microscopy. Z-stack images were collected on confocal microscope (Zeiss LSM 510 
META, Germany) with 5x and 40x objectives. Z-stack layers were separated by 1 µm, and 
slices were imaged over their total depth. Images were then processed in Fiji (ImageJ) [30]. 
Neurons in CA1 and CA3 pyramidal layers were quantified with a counting algorithm 
modified from existing “3D watershed technique” for counting cell nuclei (ImageJ macro 
developed by [31]). 
3.2.7 Electrophysiology and data analysis 
Electrical recordings were carried out by connecting the electrode contact pads on MEA to 
a 16-channel extracellular amplifier with high impedance head stage (3600, A-M Systems). 
Signals were digitized with a multiple-channel digital acquisition board (Measurement 
Computing). Sampling rate was 200 Hz per channel. Chronic data acquisition will be 
initiated on 1 DIV, and continued until 14 DIV, with short interruptions for medium supply. 
Data were recorded with dClamp software (available from authors upon request), and 
analyzed with Matlab (Mathworks). A data binning algorithm was developed for 
automated quantification of seizure-like activity in chronic recordings. Color raster plots 
were created by binning the data at 0.5 s and calculating the number of super-threshold 
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bins (represent paroxysmal events) per 10 seconds sliding window. Threshold was set at 
20 ~ 30 µV, since the system noise was about 10 µV.  
3.2.8 Statistical Methods 
We used Student’s t test for two-variable comparisons, one-way ANOVA with Holm-Sidak 
post hoc analysis for multiple variable comparisons, and Kolmogorov-Smirnov test for 
cumulative distribution analysis. Number of samples n refers to the number of cultures. 
 
3.3 Results and discussion 
3.1.1 Simulation of field potential in organotypic culture well 
In our simplified MEA design, recording electrodes were uninsulated in the organotypic 
culture well with relatively large active area (30 µm × 3 mm). Increased electrode area can 
reduce electrical noise, but also moderate detection sensitivity by averaging out field 
potentials occurring over the length of electrode. Different from normal electrophysiology 
platform, in which case the brain slice is placed in a large culture or perfusion chamber 
(~30 mm diameter, containing 1~2 ml conducting culture medium), µflow-MEA records 
from cultures that are physically confined in PDMS mini well (6 mm diameter, containing 
5~10 µl conducting culture medium).We hypothesized that electrical signal attenuation is 
highly reduced in spatially confined culture well, which offsets the loss of detection 
sensitivity. Therefore the uninsulated electrodes can still achieve good detection of field 
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potentials, particularly population electrical fields resulting from seizure-like activity that 
is characterized by highly synchronous neuronal firing over the entire culture area. 
To test this hypothesis, we built a current source model of seizure-like activity in 
hippocampal slice culture (Figure 3.2A,C). Due to the diversity of neuron geometry and 
the way neurons assemble in the hippocampus, the anatomy of hippocampal slice is defined 
by multiple neural layers: stratum oriens (o) is where the basal dendrites of pyramidal 
neurons (the principal excitatory neurons of the hippocampus) are located; pyramidal layer 
(p) contains the cell body (soma) of pyramidal neurons; stratum radiatum (r) contains apical 
dendrites of pyramidal neurons; stratum lacunosum-moleculare (lm) also contains apical 
dendrites of pyramidal neurons; dentate molecular layer (m) contains dendrites of the 
dentate granule cells; granule cell layer (g) contains cell body of the dentate granule cells. 
The cell body assembly can be observed in confocal imaging of NeuN staining (Figure 
3.2A). When spontaneous synchronized activity involves the whole hippocampus, at the 
moment that dendrites are depolarized by excitatory inputs, current sink forms in the layers 
that contain dendrites (o, r, m). Correspondingly, current source forms in the layers that 
contain cell body (p, g, CA3p). Reversely, at the moment that dendrites are hyperpolarized 
by inhibitory inputs, the current sink forms in soma layers, and current source forms in 
dendrite layers. Therefore, during dynamic activity, the current sink-source pattern will flip 
over the time [32,33]. The current sink-source pattern of epileptiform activity in 
hippocampal slice have been observed in previous works [1,34–36]. Based on these data, 
we created a simplified current source model of seizure-like activity in hippocampus with 
the whole slice synchronized. Current sink forms in o, r, m layers, and current source forms 
in p, lm, g, CA3p layers (Figure 3.2C). The current source in lm layer is probably due to 
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the formation of current quadrupoles in CA1 pyramidal neurons [33]. The current source 
density was set at 105 A/m3.   This value was estimated by multiplying synaptic current 
amplitude (200 pA, based on reported amplitude of evoked and spontaneous postsynaptic 
currents in epileptic hippocampal slice [37–40]) by neuron density in hippocampal slice (5 
× 105 mm3, based on our previous cell counting results [41]). We then simulated the field 
potential in mini culture well (diameter = 6 mm, fluid depth = 100 µm), and field potential 
in standard petri dish (diameter = 35 mm, fluid depth = 2 mm), which mimics the widely 
used submerged slice chamber [42,43]. The field potential distribution in the plane 50 µm 
above the substrate (mini culture well midpoint) is shown in Figure 3.2D. The plot of field 
potential distribution along the x and y coordinate showed that the electrical field due to 
synchronized activity is highly amplified in mini well, compared with standard well (Figure 
3.2E).   
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Figure 3.2 Simulation of field potential generated by seizure-like activity. (A) 
Hippocampal slice anatomy. Red and green lines represent opposite polarity of current 
source in each neural layer during synchronized synaptic transmission (when dendrite 
layers are receiving excitatory synaptic inputs: green, sink; red, source). (B) Slice culture 
maintained in an interface mini well (top; diameter = 6 mm, fluid depth = 100 µm), and in 
a submerged standard  well (bottom; diameter = 35 mm, fluid depth = 2 mm). (C) Current 
source pattern during seizure-like activity with whole hippocampal circuit synchronized 
(blue, sink; red, source). (D) Simulated field potential in mini well (top; white lines show 
the outline of neural layers), and standard well (bottom). The insert  zooms in on the 
hippocampal slice. Scale bar, 1 mm. (E) Field potential distribution along the x (top) and 
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y (bottom) coordinates at the middle of well (red, mini well; black, standard well). The 
simulation results refer to the horizontal plane at 50 µm from the well floor. o, stratum 
oriens; p, pyramidal layer; r, stratum radiatum; lm, stratum lacunosum-moleculare; m, 
dentate molecular layer; g, granule cell layer; CA3p, hilus, pyramidal layer of CA3c 
subregion. 
 
We then calculated the potential amplitude that can be detected by uninsulated electrode at 
different positions in the culture well (Figure 3.3A). Field potential distribution along the 
length of the electrode is shown in Figure 3.3B, and the corresponding average potential of 
each electrode position is shown in Figure 3.3B. The electrode can detect field potential 
ranging from 0.2 mV to 3.5 mV, similar to previous observed potential amplitude of 
epileptiform activity in brain slice [44–46]. We conclude that field potential is amplified 
in spatially confined mini culture well, which offsets the loss of sensitivity caused by 
increased electrode area, and the uninsulated electrode can still achieve good detection of 
seizure-like activity in hippocampal slice culture. 
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Figure 3.3 Amplitude of potential detected by microelectrodes at different positions. 
(A) Different positions of recording electrodes. (B) Field potential distribution along each 
microelectrode. (C) Average potential that is detected by each microelectrode.  
 
3.3.2 Validation of in vitro model of epileptogenesis on µflow-MEA 
We developed a system capable of operating two µflow-MEA devices with a 16-channel 
data acquisition setup (Figure 3.4A). Based on this system, we conducted a series 
experiments to validate the organotypic hippocampal culture model of epilepsy on µflow-
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MEA, through culture viability evaluation, epileptogenesis verification, and drug response 
test.  
We evaluated the culture viability by counting the number of surviving neurons at 14 DIV, 
and compared perfused µflow-MEA and control (interface method) cultures. Confocal 
imaging of NeuN staining showed similar well maintained cytoarchitecture and densely 
packed neurons in perfused and control cultures (Figure 3.4B). Neuron counts showed no 
difference between control and perfused cultures in CA3c, CA3b and CA1 subregions 
(Figure 3.4C; p = 0.366, 0.491, and 0.289, respectively, student t test, n = 9 each condition). 
This result suggested that microfluidic perfusion and chronic electrophysiology do not 
compromise the viability of organotypic cultures. 
Continuous electrical recording was conducted from 3 DIV to 16 DIV. Raster plots were 
constructed from electrical data with interictal and ictal (seizure) activities pseudocolored 
based on paroxysmal event frequency (Figure 3.4D). Electrographic seizures were defined 
as paroxysmal events (with significantly larger amplitudes than unit and multi-unit neural 
activity) that occurred for at least 10 seconds with event frequency of at least 2 Hz, and 
colored red in the raster plot. Neural activity was observed in all cultures, including unit 
and multiunit activity, population spikes, as well as epileptiform ictal and interictal-like 
activity, with examples shown in Figure 3.4D. The chronic data showed that organotypic 
cultures go through a latent period with little population activity before developing 
electrographic seizures (Figure 3.4E, n = 5). Seizure-like activity occurred after one week 
in vitro and continued in the later culture days. These activity patterns and epileptogenesis 
time course were similar to previous observations in organotypic hippocampal cultures 
maintained with traditional methods [23,24,47,48]. 
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We tested the effect of phenytoin, a first-line anticonvulsant that is used to treat epilepsy 
in human patients, on seizure-like activity in hippocampal cultures. In the phenytoin wash-
in and wash-out experiment, seizure-like activity was transiently abolished when phenytoin 
was applied and rebounded after the termination of drug application (Figure 3.4F, G, n = 
3). Thus phenytoin exerted acute, reversible anticonvulsive effects on this model, which is 
consistent with previous findings [23].  
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Figure 3.4 Epilepsy-on-a-chip model validation. (A) Photograph of the fully assembled 
system prototype, with a zoom in photo of the device, and a brightfield image of a 
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hippocampal culture maintained in the mini well with one substrate-integrated 
microelectrodes. Scale bar, 1 mm. (B-C) Culture viability validation. (B) Representative 
confocal imaging of NeurN staining in control cultures (interface methods) and 
microfluidic perfused cultures on 14 DIV, and higher magnification imaging in CA3c and 
CA3b, and CA1 regions. Scale bars as indicated in figure. (C) Neuron counts in CA3c, 
CA3b, and CA1. n = 9 each condition. (D-E) Chronic recordings reveal epileptogenesis. 
(D) Left: representative raster plot of chronic recording from 3 to 16 DIV. Color 
corresponds to the frequency of paroxysmal events, with low frequency indicated by blue 
color, and high frequency of paroxysmal events (seizures) indicated by red. Each horizontal 
line of the raster plot represents one hour of recording, with 24 lines per DIV. Right: the 
color map of interictal activity (top trace); seizures-like activity (ictal activity, bottom 
trace). (E) Incidence of ictal and interictal activity as a percentage of cultures recorded on 
MEA, with age of culture. n = 5 cultures. (F-G) Phenytoin showed anticonvulsive effect 
on this model. (F), representative recordings for each time period (control, phenytoin 
treatment, wash). (G) Seizure frequency during each period. n = 3, Error bars indicate SD. 
Statistical significance is indicated as ***, representing p < 0.001. 
 
3.3.3 Receptor tyrosine kinase (RTK) inhibitors screen results 
Before chronic screening, a short-term neurotoxicity pre-screen (0-7 DIV) was conducted 
to determine the non-toxic maximum concentrations of each inhibitors. The pre-screen 
results is shown in Table 3.1. Those concentrations were then applied to cultures for 
chronic screen in stage I (lactate and LDH assay), and stage II (chronic electrical assay).  
 
Table 3.1 Pre-screen results. 
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In stage I, we screened 12 hippocampal RTK inhibitors listed in Table 3.1, and found that 
several inhibitors showed strong reducing effect in lactate and LDH levels (Figure 3.5A). 
Lactate and LDH production reached their peaks between 14-17 DIV, as the consequence 
of established epilepsy and seizure-induced cell death [23]. We therefore used the period 
of 7-14 DIV, the time between spontaneous seizure onset and significant neuron death 
caused by chronic epilepsy, to evaluate the drug efficacy on epileptogenesis. We integrated 
the lactate and LDH production of inhibitor-treated cultures between 7-14 DIV, and 
normalized it to vehicle-treated control from the same animal (n = 3). A scatter plot of 
lactate versus LDH is shown in Figure 3.5B for individual cultures. Some lactate and LDH 
values were lower than the mean of controls by more than 3 times the mean standard 
derivation (data points that are outside the dashed circle), suggesting antiepileptogenic 
effect. Significantly lower LDH was observed for VEGF, PDGF, and cFMS inhibitors, and 
significantly lower lactate for GTP-14564, a multi-target inhibitor for c-fms, c-kit and Flt-
3, and EGFR/ErbB-2 inhibitor (one-way ANOVA with Holm-Sidak post hoc analysis, n = 
3 cultures each condition). However, a different EGFR/ErbB-2/ErbB-4 inhibitor did not 
show significant results, suggesting that inhibitor non-specificity may be responsible.  
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Figure 3.5 Screen of inhibitors by lactate and LDH. (A) Lactate and LDH data are 
shown as ratios of levels found in inhibitor-treated cultures and levels found in vehicle-
treated controls. n = 3 each condition. (B) Integrated lactate production (DIV7–14) versus 
integrated LDH production (DIV7-14), and data was normalized to controls from the same 
animal. 𝜎 = standard deviation of integrated lactate (horizontal axis) and LDH (vertical 
axis) of controls. Data are plotted for 12 RTK inhibitors. Drugs that showed strong 
reducing effect are highlighted.   
 
In stage II, a chronic electrical assay was conducted to verify the results we obtained in 
stage I. As is shown in Figure 3.4A, each screen was run by two µflow-MEA chips to test 
3 drug-treated conditions with one vehicle-treated control (n = 3 each condition, cultures 
were from the same animal). Chronic recording was initiated on 1 DIV and continued until 
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14 DIV. Drugs and vehicle were applied since 3 DIV. A representative 1 hour recording in 
12 cultures from one screen is presented in Figure 3.6A. In our preliminary data, a potential 
reducing effect in cumulative time seizing was observed in cFMS and EGFR/ErbB-2 
(Figure 3.6B). The cumulative number of seizures was also analyzed and showed similar 
results. Significant antiepileptogenic effect was revealed in cFMS inhibitor (Figure 3.6C-
G). Compared with the control, cumulative time seizing (Figure 3.6D) and cumulative 
number of seizures (Figure 3.6E) were significantly reduced in cultures treated by cFMS 
inhibitor. Cumulative distribution of normalized time seizing per day and normalized 
number of seizure per day showed significant  decrease in cFMS inhibitor-treated cultures 
(p = 0.005, and 0.009, respectively, Kolmogorov-Smirnov test; n = 5, from 2 animals). 
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Figure 3.6 Screen of inhibitors by chronic electrical assay. (A) Representative plot of 1 
hour recording, showing parallel monitoring of epileptogenesis in 12 organotypic 
hippocampal cultures (black, vehicle; blue, red and green represents different inhibitors 
treated conditions).  n = 3 each condition, cultures are from the same animal. (B) Ratios of 
cumulative time seizing in inhibitor-treated cultures and in vehicle-treated controls. n = 3 
each condition. (C) Representative chronic recordings of vehicle-treated control and cFMS 
RTK Inhibitor-treated cultures. (D-G) Antiepileptogenic effect of cFMS RTK Inhibitor. 
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(D, E) Normalized cumulative time seizing and normalized cumulative number of seizures. 
(F, G) Cumulative distribution of normalized time seizing per day and normalized number 
of seizures per day. Data was normalized to controls from the same animal. n = 5, from 2 
screens. Error bars indicate SD. ** p < 0.01, Kolmogorov-Smirnov test.  
 
In the simulation of field potential, we present a simplified current source model of seizure-
like activity in a hippocampal slice in an instant where the whole slice is synchronized. In 
this moment, the layers occupied by dendrites are activated by excitatory inputs, resulting 
in current sink formation in these layers and current source formation in soma occupied 
layers (Figure 3.2C). However, neural activity is dynamic, and at most points in time, 
seizure-like activity is propagating or synchronized in a specific neural layer [49,35]. We 
calculated the current source density using constant neuron density and synaptic current 
amplitude. However, neuron density is not homogenous throughout the hippocampal slice, 
and the amplitude of synaptic current varies depending on the strength of synaptic input. 
To build a more sophisticated model, all these factors need to be taken into account.  
To validate the in vitro model of epilepsy on our µflow-MEA device, we conducted drug 
response test of phenytoin. Interestingly, the cultures showed even higher seizure 
frequency after the phenytoin treatment termination. This might due to the long time scale 
(20 hours) of this microfluidic perfusion based wash-in and wash-out experiment. Seizure 
frequency progressively increased during epileptogenesis, even though phenytoin was 
applied for a period during this time. In our microfluidic culture platform, cultures are 
maintained at an liquid-air interface, so that the surface of the culture is not perfused. 
Therefore the applied drug can only reach the cells in the culture by diffusion, which could 
possibly explain the length of time it took to show drug effect. Our results suggest that 
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phenytoin cannot prevent epilepsy progression in this model, which agrees with previous 
observations [23]. 
In our preliminary data of the µflow-MEA based chronic electrical assay, cFMS and 
EGFR/ErbB-2 inhibitors showed potential reducing effects in cumulative time seizing 
(Figure 3.6B), confirming the LDH and lactate data. The most consistent and significant 
result was seen in cFMS inhibitor (Figure 3.6D-G), suggesting its antiepileptogenic effects. 
GW-2580, the compound’s name of the cFMS inhibitor we used in this work, has been 
reported to also inhibit Trk receptors [50]. It is important to note that conditional deletion 
or inhibition of TrkB kinase can attenuate or eliminate seizures in animal models of 
epilepsy [51–55]. Therefore, there is likelihood that the antiepileptogenic effect we 
observed in cFMS inhibitor is due to its non-specific inhibition of Trk kinases. To verify 
the antiepileptogenic properties of cFMS inhibitor, its inhibition selectivity and potential 
off target effects will be further investigated. In EGFR/ErbB-2 treated cultures, the data 
was more variable, and a larger sample size is needed to confirm the drug efficacy. The 
system described in this work represents a single unit of the scalable epileptogenesis assay 
platform: 12 cultures on 2 µflow-MEA chip, recorded by 12 channel electrophysiology 
station to test 3 drug-treated conditions and a vehicle-treated control. This system can be 
easily scaled up through additions of more units for high-throughput drug discovery.        
 
3.4 Conclusion 
We developed a hybrid µflow-MEA technology for scalable chronic electrical assay of 
epileptogenesis in organotypic hippocampal culture model. The simplified MEA electrode 
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design rendered cost-effective device without compromising the sensitive detection of 
seizure-like activity. As a proof of concept, µflow-MEA based chronic electrical screening 
of inhibitors of hippocampal RTKs confirmed the results of biochemistry assay and 
identified inhibitors with antiepileptogenic effects. This epilepsy-on-a-chip screening 
platform provides a rapid dissection of complex signaling pathways associated with 
epileptogenesis, paving the way for high-throughput antiepileptogenic drug discovery. 
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Chapter 4 
Disease model validation: Culture medium study 
 
 
 
4.1 Motivation   
Brain insults, including traumatic brain injury, trigger a series of changes at molecular, 
cellular, and network levels, that can cause epilepsy [1,2].  It has been hypothesized that 
the triggering event of epileptogenesis in organotypic cultures is the trauma of brain slice 
preparation [3].  In cultures, this trauma results in axonal and dendritic reorganization [4–
8] and glial activation [9,10] that are associated with epileptogenesis. In this view, 
organotypic cultures are an in vitro analogue of animal models of traumatic brain injury-
induced epileptogenesis [11–13]. However, unlike brain tissue in vivo, organotypic slices 
are maintained in an artificially controlled environment. It may be possible that 
epileptogenesis in organotypic cultures is driven by artificial environmental factors. Here, 
we test this hypothesis by focusing on the most artificial aspect of organotypic culture 
environment: the culture medium.   
The work described in this chapter has been published in 
“Epileptogenesis in organotypic hippocampal cultures has limited 
dependence on culture medium composition” by Liu J, Saponjian Y, 
Mahoney MM, Staley KJ, and Berdichevsky Y, PLoS ONE. 2017;12: 
e0172677. 
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Mammalian tissues must be bathed in a mixture of metabolic substrates, hormones and 
growth factors (culture medium) to maintain them in vitro longer than 24 hours.  Early 
versions of culture media were often supplemented by actual blood-derived serum [14,15].  
Since concentrations of hormones and metabolites can sometimes vary significantly in 
samples of animal serum, fully chemically-defined media were developed to enhance 
reproducibility [16,17]. We have previously used both serum-supplemented and 
chemically defined media to maintain organotypic hippocampal cultures, and found that 
epileptogenesis occurs in both types of media [18,19]. One concern is that chemically 
defined culture medium is based on the composition of blood plasma rather than 
cerebrospinal fluid (CSF).  Epileptogenesis in vivo may be enhanced by the opening of the 
blood-brain barrier (BBB) after brain injury [20,21].  This enhancement is thought to arise 
from direct exposure of brain tissue to components of blood that normally do not cross 
BBB, or to compounds that are present in blood at different concentration than in CSF 
[22,23].  Therefore, it may be possible that epileptogenesis in organotypic cultures is not 
triggered by the trauma of dissection, but by exposure of hippocampal tissue to a cocktail 
of compounds that are present at much lower concentration or not present at all in normal 
CSF. 
Organotypic slices are prepared from perinatal (postnatal day 7) rodent brain, so the culture 
media is typically that used for the culture of postnatal neurons (Neurobasal-A, the NeurA 
column in Table 4.1) with B27 supplement (Table 4.2). It can be readily seen that 
concentrations of glucose, potassium, and magnesium in Neurobasal-A are substantially 
different than those found in CSF [24–26].  Some of these differences, such as increased 
potassium and decreased calcium and magnesium concentrations, may contribute to in 
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vitro hyperexcitability [22,27].  In addition, many amino acids are contained in Neurobasal-
A at significantly higher concentrations than in CSF [28–31]. Altered concentrations of 
amino acids such as glycine, serine, leucine, isoleucine, valine, phenylalanine and others 
are found in metabolic epilepsies [32,33], and might also play a role in development of 
spontaneous epileptiform activity in organotypic cultures.  Neurobasal-A medium is 
usually supplemented with B27, which contains Bovine Serum Albumin (BSA), insulin, 
transferrin, progesterone, putrescine, and selenium along with others for a total of 20 
components (Table 4.2). These components may also play a role in epileptogenesis [34]. 
 
Table 4.1 Composition of Neurobasal-A, customized medium (CST) and CSF based 
medium (CBM). 
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Table 4.2 Composition of B27 medium supplement. 
 
In this work, we tested the hypothesis that the composition of culture medium influences 
epileptogenesis in organotypic hippocampal cultures. To do this, we altered the 
concentration of individual components of the media and measured the effects on 
epileptogenesis in this model. 
 
4.2 Experimental methods 
4.2.1 Culture media preparation 
Customized culture media were prepared with different compositions and concentrations 
of electrolytes, amino acids, and glucose (all from Sigma) as described in the text.  The 
osmolarity of all custom media was matched to Neurobasal-A (240 – 260 mOsm/kg) by 
adjusting the NaCl concentration. Unless otherwise indicated, all culture media were 
supplemented with bovine serum albumin (BSA) (250 mg/L: physiological range of 
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albumin in healthy CSF is 70 – 266 mg/L [35–38]), insulin (3.5 mg/L), selenium (14 µg/L), 
from Sigma, and glutaMAX (0.5 mM) and gentamicin (30 mg/L), from Life Technologies.  
In experiments addressing role of B27 components, concentrations of BSA, insulin and  
4.2.2 Morphology Analysis 
Morphology analysis is described in detail in Chapter 3. Here, slice brightness was 
quantified by calculating mean greyscale value of the slice area minus the background in 
bright field images (Fiji/ImageJ).  
4.2.3 Electrophysiological recordings and data analysis 
Cover slips with cultures were transferred to a 35 mm petri dish and placed in an interface 
chamber perfused with culture medium at 37 °C. Extracellular field potential recordings 
were performed using tungsten microelectrodes (0.1 MOhm) connected to an amplifier 
(RZ2, Tucker Davis Technologies) fitted with high-impedance multiple-channel pre-
amplifier stage (PZ2-64, Tucker Davis Technologies) (band-pass 1 Hz-3 kHz, gain ×1000). 
Sampling rate was 6 kHz per channel. To record the population activity and multiple unit 
activity, microelectrodes were placed in CA3 pyramidal cell layer. OpenEx (Tucker Davis 
Technologies) and Matlab (MathWorks) were used for signal processing and data analysis. 
Ictal events (electrographic seizures) were defined as paroxysmal events of much larger 
amplitude than background multiple unit activity and lasting longer than 10 s, including 
discrete shorter paroxysmal events that occurred with event frequency of at least 2 Hz for 
at least 10 s.  
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4.2.4 Nissl and NeuN staining and image analysis 
For Nissl staining, cultures were fixed in 4% paraformaldehyde, permeabilized for 1 h in 
0.3% Triton-X on a shaking platform, and stained with propidium iodide (Invitrogen; 1 
mg/ml stock) diluted 1:250 in phosphate-buffered saline (PBS) for 5 h. NeuN staining was 
carried out as described in Chapter 2. Slices were then washed and mounted for confocal 
microscopy. Z-stack images were collected on a confocal microscope (Zeiss LSM 510 
META, Germany) with 40× objective. Z-stack layers were separated by 2 µm, and slices 
were imaged over their total depth.  Images were then processed in Fiji (ImageJ). Neurons 
in CA1 and CA3 pyramidal layers were quantified with a counting algorithm modified 
from existing “3D watershed technique” for counting cell nuclei (ImageJ macro developed 
by [42]).   
4.2.5 Statistical Methods 
We used Student’s t test for two-variable comparisons, one-way ANOVA with Holm-Sidak 
post hoc analysis for multiple variable comparisons, and z-test for seizure-like event 
incidence comparison. Number of samples n refers to the number of cultures or the number 
of cells as indicated. 
 
4.3 Results 
The summary of our experiments is provided in chart form in Figure 4.1.  We focused on 
identifying components of B27 and Neurobasal-A that were vital for viability of 
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organotypic hippocampal cultures. We then simplified the culture medium, and varied 
concentrations of essential components to determine effects on epileptogenesis. 
 
Figure 4.1 Summary of experiments. 
 
4.3.1 Replacement of B27 supplement with BSA, insulin and selenium 
We hypothesized that only BSA and a subset of components of B27 with concentrations 
indicated in Table 4.2 (these components make up the widely used N2 supplement) are 
essential to maintain viable slice cultures.  The following compositions were tested: BSA 
only; BSA and insulin (BSA + ins); BSA, insulin and selenium (BSA + ins + Se); BSA + 
insulin + Se + transferrin + putrescine + progesterone; and B27. The concentration of each 
component is listed in Table 4.2.  Supplements were added to Neurobasal-A medium, 
which was further supplemented with GlutaMAX and gentamycin as described in section 
4.2.1.  Confocal images taken on 8 DIV showed that cultures kept in medium supplemented 
with BSA only or with BSA + insulin had missing or fragmented pyramidal layers, 
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indicating poor neuronal survival (Figure 4.2A). Slices maintained in media with 3 other 
supplements showed intact pyramidal layers and maintained hippocampal morphology. To 
further compare these 3 supplements, we quantified the neuron numbers in CA3c, CA3b 
and CA1. Compared with B27 group, BSA+ins+Se+transferrin+putrescine+progesterone 
group had a significantly lower number of neurons in CA3b (ANOVA with post hoc Holm-
Sidak analysis in this and subsequent statistical tests, p = 0.007, n = 3 cultures, each 
condition) (Figure 4.2B). BSA + insulin + selenium group showed similar neuron numbers 
to B27 group in CA3c, CA3b and CA1 (p = 0.222, 0.410, 0.398, respectively, n = 3 cultures, 
each condition). We conclude that BSA, insulin and selenium were essential and sufficient 
supplements to Neurobasal-A medium for neuronal survival in organotypic hippocampal 
cultures until 8 DIV.  
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Figure 4.2 Essential components of B27 supplement. (A) Low magnification confocal 
images of Nissl staining in cultures at 8 DIV, conditions are indicated on the left side of 
images, scale bars, 500 µm. (B) Corresponding neuron counts in CA3c, CA3b and CA1. 
Statistical differences are indicated for comparisons between B27 group versus other 
groups. Error bars indicate SD. Statistical significance is indicated as **, representing p < 
0.01. (C) Confocal images of Nissl staining in CA3c, CA3b and CA1, scale bars, 50 µm. n 
= 3 cultures, each condition.  
 
4.3.2 Reduction of selenium and insulin affects cell survival 
We modified concentrations of each component of the simplified supplement (BSA + 
insulin + selenium) to investigate their effect on cultures. Following concentrations were 
tested: for BSA, 0.4x (BSA concentration equal to 0.4 times that listed in Table 4.2), 1x 
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(BSA concentration equal to that listed in Table 4.2), 4x (4 times) and 10x (10 times); for 
selenium, 0x (no selenium), 0.1x (selenium concentration equal to 1/10 of that listed in 
Table 4.2), 1x (selenium concentration equal to that listed in Table 4.2), 10x (10 times); 
for insulin, 0.01x (insulin concentration is 1/100 of listed), 0.1x (insulin concentration 
equal to 1/10 of that listed in Table 4.2), 1x (insulin concentration equal to that listed in 
Table 4.2), and B27.  The concentration of only one component was varied in each 
experiment while the other components were included at concentrations found in Table 4.2.  
It was not possible to reduce albumin below 100 mg / L due to reductions in the uniformity 
of wetting of the hippocampal slice surface by the media.  Brightfield microscope images 
were taken at 21 DIV. We measured LDH and lactate concentrations in spent culture media. 
Data were from medium collected on 3, 7, 10, 14, 17 and 21 DIV. There were no significant 
differences in gross culture morphology or LDH and lactate concentrations in medium 
containing different concentrations of BSA (Figure 4.3A). Cultures in medium with 0x 
selenium had undistinguishable neural layers, indicating poor survival (Figure 4.3B). 
Compared with 1x selenium group, 0x selenium group had significantly higher LDH at 7 
DIV, 10 DIV, 14 DIV and 17 DIV (p < 0.001 for 7, 10, 14 DIV, p = 0.01 for 17 DIV, n = 
3 cultures, each condition) and significantly lower lactate at 10 DIV, 14 DIV, 17 DIV, 21 
DIV (p < 0.001 for all these days, n = 3 cultures, each condition), confirming morphology 
results and indicating that selenium is essential for culture survival.  No differences in 
morphology or lactate and LDH concentrations were observed between cultures 
supplemented with 0.1x, 1x, or 10x selenium.  Cultures in medium with 0.01x insulin were 
brighter and smaller than cultures with 0.1x or 1x insulin or B27 (Figure 4. 3C; inverted 
greyscale values of cultures were 123.41 ± 8.35, 142.13 ± 8.31, 149.47 ± 3.40 and 132.72 
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± 7.63 for 0.01x, 0.1x, 1x and B27 group respectively, n = 3 cultures, each condition.  A 
significant difference was found in comparison of 0.01x vs. 1x group, p = 0.007, n = 3 
cultures, each condition). Compared with 1x insulin group, 0.01x insulin group had 
significantly lower LDH from 10 DIV to 21 DIV (p < 0.001 for 10, 14, 17 DIV, p = 0.005 
for 21 DIV, n = 3 cultures, each condition) and significantly lower lactate from 7 DIV to 
21 DIV (p < 0.001 for 7, 10, 14 DIV, p = 0.007 for 17 DIV, p = 0.003 for 21 DIV, n = 3 
cultures, each condition).  However, LDH concentration for 0.01x group was moderately 
higher on DIV 3 than for cultures supplemented with higher concentrations of insulin or 
with B27.  This, together with smaller size of the 0.01x insulin cultures, suggested that 
more cells died by DIV 3 due to lack of sufficient concentration of insulin, leading to lower 
lactate production in these cultures later on.   
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Figure 4.3 Effects of different concentrations of BSA, selenium, and insulin. (A-C) 
Left: brightfield images of cultures maintained in media with indicated concentrations of 
BSA, selenium or insulin, scale bars represent a distance of 500 µm; Right: time course of 
LDH and lactate concentration in culture supernatant of cultures; n = 3 cultures, each 
condition. Error bars indicate SD. Significant statistical differences are indicated for 
comparison of 0X selenium versus 1X selenium and 0.01X insulin versus 1X insulin, with 
***p < 0.001, **p < 0.01. 
 
We further investigated the influence of insulin concentration on culture survival. We used 
the following conditions: 0x (no insulin), 0.01x (insulin concentration is 1/100 of that listed 
in Table 4.2), and 1x. Confocal images taken on 8 DIV showed that 0x group had smaller 
slice area compared with other groups (Figure 4.4A). We measured the slice area and a 
significant difference was seen between the 0x group and 1x group (p = 0.011, n = 3 
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cultures, each condition). We quantified the number of neurons in CA3c, CA3b and CA1 
(Figure 4.4B, left chart).  However, we found that due to the more compact size of 0x 
insulin cultures, a larger proportion of the pyramidal cell layer would fit into a single field 
of view for those cultures compared to 0.01x and 1x cultures.  To arrive at a correct relative 
number of neurons between the cultures, we corrected neuronal counts with normalized 
total slice area (Figure 4.4B, right chart). Compared to the 1x group, the 0x group and 0.01x 
group showed significantly lower neuron numbers in CA1 (before slice area correction: p 
= 0.002 for 0x group, p = 0.011 for 0.01x group, n = 3 cultures, each condition; after slice 
area correction: p < 0.001 for both conditions). We inspected the size of individual neurons 
and found that 0x group and 0.01x group had smaller neurons compared to the 1x group 
(Figure 4.4D). A significant difference was seen between the 0x group and 1x group (p < 
0.001, n = 30 cells, each condition). We concluded that insulin affects neuronal size, 
survival and slice size. However, insulin concentrations that were reduced by a factor of 
10 from the standard N2 levels had no significant effects on our measures of the health of 
the slice cultures. In subsequent experiments, we supplemented all media with BSA, insulin 
and selenium at concentrations listed in Table 4.2, since these concentrations were optimal 
for neural survival by DIV 8. 
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Figure 4.4 Insulin enhances neuronal survival. (A) Low magnification confocal images 
of Nissl staining in cultures at 8 DIV, conditions are indicated on the left side of images, 
scale bars, 500 µm. Chart shows effect of insulin on slice area; (B) Left: neuron counts in 
CA3c, CA3b and CA1; Right: neuron counts corrected by the normalized slice area. n = 3 
cultures, each condition. Statistical differences are indicated for comparison between 1X 
group and other groups. (C) Representative confocal images of Nissl staining in CA3c, 
CA3b and CA1, scale bars, 50 µm. (D) Left: representative confocal images of neurons in 
CA3c, scale bars represent a distance of 5 µm; Right:  corresponding cell size in CA3c. n 
= 30 cells, each condition. Significant statistical differences are indicated for comparison 
of 0X group versus 1X group. Error bars indicate SD. Significant differences are labeled 
as *p < 0.05, **p < 0.01 and ***p < 0.001. 
 
4.3.3 Identification of essential components of Neurobasal-A 
We grouped the hypothesized non-essential components into three sets listed in Figure 
4.5A.  We then replicated  Neurobasal-A by combining BME amino acids solution (B6766, 
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Sigma, 1:12.5 dilution) and BME vitamins solution (B6891, Sigma, 1:25 dilution) with 
other components in Neurobasal-A formulation in appropriate concentrations (Table 4.1, 
NeurA columns). Suspected noncritical components were included in the replicate 
experimental group, or excluded as indicated. Cultures were maintained in replicated 
NeurA or replicated NeurA with set 1, set 2, or set 3 excluded (-set1, -set2, -set3 
experimental groups). Brightfield microscope images taken on 21 DIV showed that 
cultures without glycine and L-serine (-set1) were significantly brighter than other groups 
(Figure 4.5B; inverted greyscale = 152.60 ± 6.74, 110.28 ± 9.29, 148.85 ± 2.98 and 152.65 
± 7.39 for replicate, -set1, -set2 and –set3 group respectively; p < 0.001 for –set1 vs. 
replicate, n = 3 cultures, each condition). Slices in –set2 and –set3 had morphologies 
similar to control (replicated NeurA) slices. Group lacking set1 was found to have lower 
LDH and lactate concentrations than the other three groups from 14 DIV to 21 DIV. 
Significant differences in lactate between –set1 group and NeurA replicate group appeared 
on  14, 17, 21 DIV (p < 0.001, p = 0.004, p = 0.007, respectively, n = 3 cultures, each 
condition). Based on the altered morphology, LDH, and lactate, we conclude that glycine 
and L-serine play a role in cell survival and activity.  On the other hand, exclusion of set2 
or set3 had no noticeable effect on culture morphology or LDH and lactate release. In 
subsequent experiments, we used NeurA medium with the noncritical sets 2 and 3 excluded, 
which we termed customized medium (CST, Table 4.1).  The role of glycine and L-serine 
was investigated further in experiments described in the section 4.3.4. 
Based on CST, we generated media with different concentrations of essential amino acids:  
control (essential amino acid concentrations equal to those listed for CST), 0.1x (essential 
amino acid concentrations equal to 1/10 of those listed for CST), 0.01x (1/100) and 0x (no 
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essential amino acids). By 7 DIV, cultures in 0x group were significantly darker than 
control cultures, indicating poor survival (Figure 4.5C; inverted greyscale values were 
135.19 ± 3.42, 124.77 ± 3.87, 144.46 ±15.32 and 170.53 ± 10.56 for control, 0.1x, 0.01x 
and 0x group respectively; p = 0.001 for  0x vs. control group, n = 3 cultures, each 
condition). Neural layers became undistinguishable in 0x cultures by 7 DIV. 0.01x and 0x 
group had significantly higher LDH than control at 7 DIV (p < 0.001, n = 3 cultures, each 
condition). We conclude that concentrations of essential amino acids lower than 1/100 of 
what is found in Neurobasal-A are insufficient for culture survival.  We then compared 
0.1x and control groups (Figure 4.5D). No observable differences in culture morphology 
were found in microscope images at 14 DIV. However, 0.1x group had significantly higher 
LDH than control at 10 DIV (p = 0.03, n = 3 cultures, each condition) and 14 DIV (p = 
0.006, n = 3 cultures, each condition). Thus, we conclude that reduction of all essential 
amino acid concentrations was detrimental to culture survival.  
We then examined the possibility that we could reduce seizure activity in organotypic slice 
cultures by reducing the concentrations of some of the essential amino acids, without 
increasing cell death.  We focused on the amino acids that play a role in metabolic epilepsy: 
leucine, isoleucine, phenylalanine and valine (Figure 4.5E). Control cultures were 
maintained in CST with all essential amino acids, -leucine & isoleucine cultures were 
maintained in CST without leucine and isoleucine, and -4S cultures were maintained in 
CST without leucine, isoleucine, phenylalanine, and valine.  The cultures of the last two 
groups had a deformed shape with a hole in the slice center, and much thinner neural layers 
compared with the control group at 10 DIV. The control group showed significantly higher 
LDH than the other two groups at 7 DIV (p < 0.001 for both groups), 10 DIV (p = 0.009 
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for –leucine and isoleucine group, p = 0.035 for -4S group), and 14 DIV (p < 0.001 for 
both groups).  In this case, early cell death in –leucine & isoleucine and -4S cultures 
(detected by poor morphology of these cultures) resulted in lower LDH at later time-points, 
due to fewer surviving cells.  We conclude that leucine, isoleucine, phenylalanine, and 
valine are essential for organotypic hippocampal culture viability.  
We also excluded all vitamins (-vitamins mix), and compared it with 1x vitamins 
concentration medium (control). Microscope images at 10 DIV revealed that the -vitamins 
mix group slices shrank, with significantly darker neural layers than control cultures, 
despite no significant difference in LDH (Figure 4.5F; inverted greyscale = 125.77 ± 8.21 
and 157.73 ± 0.30 for control and –vitamins mix group respectively, p = 0.005, n = 3 
cultures, each condition). We conclude that exclusion of vitamins increased cell death in 
cultures. 
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Figure 4.5 Neurobasal-A simplification. (A) List of hypothesized noncritical components. 
(B) Left: brightfield microscope images at 21 DIV, scale bars represent a distance of  500 
µm; Right: time course of LDH and lactate concentration in spent culture media from 
cultures treated with replicated NeurA, or NeurA without set1, set2 or set3; n = 3 cultures, 
each condition. Significance is shown for replicate group versus –set1 group. (C) Cultures 
maintained in the presence of different concentrations of essential amino acids. Top: 
photomicrographs at 7 DIV. Scale bars, 500 µm; n = 3 cultures, each condition. Statistical 
significance is indicated for 0x group and 0.01x group versus control. (D) Cultures 
maintained in the presence of reduced and control concentrations of amino acids. Images 
are from 14 DIV; n = 3 cultures, each condition. (E) Evaluation of the removal of 4 
metabolic epilepsy-related essential amino acids (4S: leucine, isoleucine, phenylalanine 
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and valine).  Images are from 10 DIV; n = 3 cultures, each condition. Statistical differences 
are shown for experimental groups versus control. (F) Cultures maintained in the presence 
of 1x (control) and without vitamins (- vitamins mix) and corresponding greyscale and 
LDH measurements. Images are from 10 DIV; n = 3 cultures, each condition. Error bars 
indicate SD. Significances are labeled as ***p < 0.001, **p < 0.01 and *p < 0.05. 
 
4.3.4 Reduction of non-essential amino acids affects cell survival  
We investigated glycine and L-serine in more detail. We maintained cultures in media 
containing different concentrations of glycine or L-serine (only one of those amino acids 
was present in media described in this paragraph and Figure 4.6A and B.  Base 
concentration (1x) of glycine or L-serine was 0.4 mM as in NeurA.  0x medium contained 
neither glycine nor L-serine. Confocal images of cultures stained with anti-NeuN neuron-
specific antibody were taken at 21 DIV (Figure 4.6A). Cultures maintained in 0x and 0.01x 
glycine had very few neurons remaining by 21 DIV. NeuN staining in 0.1x glycine group 
revealed distinct neuron layers similar to 1x group. Neuronal counts in area CA1 revealed 
that compared with 1x group, significantly less neurons remained in 0x (p < 0.001, n = 3 
cultures, each condition) and 0.01x (p = 0.009, n = 3 cultures, each condition) glycine 
groups, while more neurons remained in 0.1x (p = 0.041, n = 3 cultures, each condition) 
group. Cultures maintained in 0x serine group cultures shrank and lost hippocampal 
morphology, while cultures maintained in 0.01x serine had distinct CA1 and CA3 neuronal 
layers but few neurons in DG (Figure 4.6B). In 0.1x and 1x L-serine groups, cultures had 
well preserved and distinct pyramidal and granule neuron layers (bright NeuN staining). 
The number of neurons in CA1 was significantly lower in 0x L-serine group (p < 0.001, n 
= 3 cultures, each condition) compared with 1x group. There were no significant 
differences between numbers of CA1 neurons in 0.01x, 0.1x and 1x L-serine groups.  Based 
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on CA1 neuron counts and preservation of DG, we conclude that concentrations of glycine 
and L-serine less than 0.1x (0.04mM) were insufficient to support culture survival.  
We then examined whether combined glycine and L-serine could support neurons in 
organotypic cultures at lower concentration than glycine or L-serine alone. We compared 
lactate and LDH release in media containing 0.01 mM glycine and L-serine and in medium 
containing 0.4 mM glycine and L-serine (CST medium) (Figure 4.6C). Slightly less lactate 
and LDH was released in medium with 0.01 mM glycine and serine compared to medium 
with 0.4 mM glycine and serine, although results were not statistically significant except 
for LDH on 17 DIV  (p = 0.036, n = 3 cultures, each condition). We conclude that when 
both L-serine and glycine are included in culture media, concentrations can be reduced to 
0.01 mM without adversely affecting cell survival.  Slightly higher LDH and lactate release 
in medium with higher glycine and serine concentrations pointed to a potential pro-
epileptic effect of these amino acids. 
 107 
 
 
Figure 4.6 Cultures in media with different glycine and serine concentrations. (A) Left: 
low magnification confocal images of NeuN staining in cultures at 21 DIV, glycine 
concentrations are indicated on left side of images, scale bars, 500 µm; Middle: 
representative confocal images of NeuN staining in CA1, scale bars, 50µm; Right: 
corresponding CA1 neuron counts; n = 3 cultures, each condition. Statistical differences 
are indicated for comparisons between 1x group versus other groups. (B) Cultures 
maintained in different concentrations of serine. Significances are indicated for 0x group 
versus 1x group; n = 3 cultures, each condition. (C) Lactate and LDH results for cultures 
treated with combined glycine and serine, n = 3 cultures, each condition. Error bars 
represent SD. Significant differences are labeled as *p < 0.05, **p < 0.01 and ***p < 0.001. 
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4.3.5 Modification of electrolyte and glucose concentrations affects cell survival and 
ictal activity  
Concentrations of glucose, calcium, magnesium and potassium in CST are different from 
those found in rat CSF. We modified the concentrations of these components to investigate 
their effect on cultures.  The following concentrations were tested: for glucose, 11 mM 
(glucose concentration used in typical artificial CSF (aCSF) for acute slice experiments 
[19]), 15 mM, 20 mM, and 25 mM; for calcium, 0.5 mM, 1 mM, 2 mM ( [Ca2+] used in 
typical aCSF), 4 mM; for magnesium, 0.5 mM, 1.3 mM ( [Mg2+] used in typical aCSF), 2 
mM, and 4 mM; for potassium, 2 mM, 3.5 mM ([K+] used in typical aCSF), 5 mM, and 8.5 
mM. Concentration of only one medium component was varied in each experiment; other 
components were included at concentrations found in CST (Table 4.1).  Brightfield 
microscope images were taken at 14 DIV. There were no differences in culture morphology 
or LDH and lactate in media containing different concentrations of glucose (Figure 4.7A). 
Cultures in medium with [Ca2+] = 4 mM had dark edges around neuron layers, indicating 
that cell death occurred (Figure 4.7B). Compared with [Ca2+] = 2 mM group, [Ca2+] = 4 
mM group had significantly higher LDH (p = 0.004, n = 3 cultures, each condition) and 
significantly lower lactate (p < 0.001, n = 3 cultures, each condition) at 7 DIV, confirming 
morphology results and indicating that high Ca2+ concentration is toxic for organotypic 
hippocampal cultures. Cultures in medium with [Mg2+] = 4 mM had significantly brighter 
neural layers than cultures in media with lower [Mg2+], which is potentially due to lower 
dead cell accumulation (Figure 4.7C; inverted greyscale = 144.94 ± 1.19, 146.73 ± 3.43, 
141.21 ± 3.60 and 130.20 ± 2.08 for 0.5 mM, 1.3 mM, 2.0 mM and 4.0 mM group 
respectively; p < 0.001 for 4.0 mM vs. 1.3 mM, and 4.0 mM vs. 0.5 mM, p = 0.04 for 4.0 
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mM vs. 2.0 mM, n = 3 cultures, each condition). Interestingly, cultures in [Mg2+] = 2 mM 
and [Mg2+] = 4 mM groups had significantly lower LDH and lactate release compared with 
[Mg2+] = 1.3 mM group at 10 DIV (p = 0.001, LDH, n = 3 cultures, each condition, and p 
= 0.006, lactate, n = 3 cultures, each condition). Cultures in media containing [K+] = 5 mM 
and [K+] = 8.5 mM group had better morphology (lighter, clearer neuronal layers) than 
cultures in [K+] = 3.5mM, while cultures in [K+] = 2 mM group had the worst morphology 
(dark, neuronal layers not visible) (Figure 4.7D). [K+] = 8.5 mM group released 
significantly less LDH than [K+] = 3.5 mM group at 10 and 14 DIV (p = 0.007 and p = 
0.008, respectively, n = 3 cultures, each condition). There were no significant differences 
found in lactate release by cultures in media with different [K+].  Brighter neural layers and 
lower LDH in [K+] = 8.5 mM group indicated that high concentration of K+ was 
neuroprotective (inverted greyscale = 169.73 ± 4.27, 168.07 ± 6.20, 152.08 ± 0.45 and 
143.69 ± 4.17 for 2.0 mM, 3.5 mM, 5.0 mM and 8.5 mM group respectively; p < 0.001 for 
8.5 mM vs. 2.0 mM, and 8.5 mM vs. 3.5 mM, p = 0.003 for 5.0 mM vs. 2.0 mM, p = 0.006 
for 5.0 mM vs. 3.5 mM, n = 3 cultures, each condition). This finding was surprising, since 
acute application of high [K+] was previously found to increase ictal activity in acute 
hippocampal slice preparations [43].  The potential anticonvulsant effect of elevated [Mg2+] 
in organotypic cultures, evidenced by lower lactate production, is consistent with data from 
other models [44,45]. 
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Figure 4.7 Modification of glucose and electrolyte concentrations affects cell survival 
and ictal activity. (A-D) Left: brightfield images of cultures maintained in media with 
indicated concentrations of glucose, Ca2+, Mg2+, or K+ at 14 DIV, scale bars, 500 µm; Right: 
time course of LDH and lactate release into culture medium. n = 3 cultures, each condition. 
Error bars indicate SD.  Concentrations of ions that correspond to rat CSF are underlined 
and indicated by solid symbols.  Significant statistical differences are indicated for 
comparison of 4 mM Ca2+, 4 mM Mg2+ and 8.5 mM K+ versus CSF concentrations of 
corresponding ions. , with **p < 0.01 and ***p < 0.001.  
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4.3.6 CSF-based medium can support organotypic hippocampal cultures 
We hypothesized that changing concentrations of glucose, Ca2+, Mg2+, and K+ 
simultaneously may produce different effects than changing their concentrations 
individually.  We made another medium, defined as CSF-based medium (CBM). CBM has 
the same components as CST, but concentrations of electrolytes were changed to reflect 
concentrations in rat CSF, while glucose concentration was changed to match typical 
concentration used in aCSF for acute slice experiments [46] (Table 4.1). Cultures 
maintained in CST or CBM were compared to cultures maintained in NeurA (Figure 4.8A). 
Compared with NeurA slices, CST and CBM cultures showed similar well-preserved 
hippocampal morphology with clear neuronal layers. No significant differences in LDH 
release were found between the three experimental groups, confirming morphology results 
(n = 3 cultures, each condition).  On the other hand, significantly lower lactate release in 
CST and CBM groups were found in comparison to the NeurA group starting from 7 DIV 
to 21 DIV (at 7 DIV, 10 DIV, 14 DIV, 17 DIV and 21 DIV, for CST versus NeurA, p = 
0.003, 0.015, 0.023, 0.012, 0.002, respectively; for CBM versus NeurA, p = 0.002, 0.001, 
0.001, 0.002, 0.006, respectively, n = 3 cultures, each condition).  Significant differences 
were also found between CST and CBM groups at 10 DIV and 14 DIV (p = 0.038, and 
0.036, respectively, n = 3 cultures, each condition).  
Confocal images of NeuN-stained cultures showed that pyramidal neuronal layers were 
well organized and densely packed in both NeurA and CBM cultures at 10 DIV (Figure 
4.8B). The numbers of surviving neurons were not different between NeurA and CBM 
cultures in either CA1 (p = 0.663, student t test, n = 3 cultures, each condition) or CA3 (p 
= 0.317, student t test, n = 3 cultures, each condition).  
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To further investigate the reduced lactate production in CBM and CST vs. NeurA culture 
media, we quantified electrographic seizures (ictal events) in NeurA and CBM cultures 
from 0 to 14 DIV.  To compare effects of NeurA and CBM, data were grouped into four 
time periods: 0-3 DIV, 4-7 DIV, 8-10 DIV, and 11-14 DIV (at each time point, for NeurA: 
n = 17 from 6 animals, 9 from 6 animals, 8 from 4 animals, 10 from 4 animals, respectively; 
for CBM: n = 15 from 6 animals, n = 8 from 6 animals, n =10 from 3 animals, n = 10 from 
4 animals, respectively; 10 animals were used in total, n represents the number of cultures).  
Seizure incidence was slightly, but not significantly lower in cultures maintained in CBM 
compared to cultures maintained in NeurA during all time periods (Figure 4.8C, D; p = 
0.141, 0.742, 0.769, 0.348 for 0-3, 4-7, 8-10, 11-14 DIV, respectively, z-test). We then 
examined seizure frequency, duration, and total time seizing per hour only in cultures with 
seizures.  The only significant reduction in average seizure duration was found in CBM vs. 
NeurA during the 4 - 7 DIV time period (p = 0.039, n = 6 for NeurA, n = 5 for CBM).   
Thus, CBM cultures were somewhat less epileptic than NeurA cultures, which matches 
well with the differences in lactate between cultures maintained in CBM and NeurA media. 
However, electrical recordings also revealed that number of seizures per hour (p = 0.094 
on 8-10 DIV, n = 6 for NeurA, n = 7 for CBM; p = 0.344 on 11-14 DIV, n = 8 for NeurA, 
n = 5 for CBM, n represents the number of cultures), and time seizing per hour (p = 0.201 
on 8-10 DIV, n = 6 for NeurA, n = 7 for CBM; p = 0.713 on 11-14 DIV, n = 8 for NeurA, 
n = 5 for CBM) were slightly but not significantly lower in CBM compared to NeurA after 
8 DIV. In cultures that had electrographic seizures, average seizure duration was actually 
slightly, but not significantly higher in CBM compared to NeurA at 11 – 14 DIV (p = 0.057, 
n = 8 for NeurA, n = 5 for CBM). 
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Figure 4.8 Comparison between NeurA, CST and CBM media. (A) Brightfield images 
at 10 DIV. Scale bars, 500 µm. Time course of LDH and lactate concentration in culture 
supernatant; n = 3 each condition per time point. Error bars indicate SD. Statistical 
significant differences are indicated for CBM and CST versus NeurA, with **p < 0.01. (B) 
Representative confocal images of CA1 and CA3 area of NeuN-stained organotypic 
hippocampal cultures at 10 DIV. Scale bars, 50 µm. Neuron counts in CA1 and CA3 are 
shown on the right; n = 3 each condition. (C) Representative recordings of electrographic 
seizure-like events in organotypic cultures on 10 DIV. Seizure detail is shown in lower 
traces. Red lines indicate the threshold for paroxysmal event detection. (D) Electrographic 
seizures (ictal events) in NeurA and CBM in electrographic recordings of seizing slices. 
For 0-3 DIV, 4-7 DIV, 8-10 DIV, 11-14 DIV,n = 17, 9, 8, 10 for NeurA, n = 15, 8, 10, 10 
for CBM, respectively. n represents the number of cultures. *p < 0.05.  Error bars represent 
95% confidence intervals for incidence of ictal activity and SD for other graphs.  
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4.3.7 Epileptogenesis occurs independently of medium composition 
Previous experiments revealed that reduction of glycine and L-serine concentrations to 
0.01 mM and increase of [Mg2+] to 2 mM significantly decreased cell death and reduced 
lactate production (Figure 4.6C and 4.7C). We integrated these two modifications into a 
modified medium, and compared it with CBM. Microscope images at 14 DIV revealed that 
cultures in modified media had significantly brighter neural layers than cultures in CBM 
(Figure 4.9A; inverted greyscale = 155.22 ± 8.37 and 134.15 ± 5.06 for CBM and modified 
medium group respectively, p = 0.038, n = 3 cultures, each condition). Cultures maintained 
in modified medium released significantly less LDH than slices in CBM at 14 DIV (p = 
0.048, n = 3 cultures, each condition).   No significant differences were observed in lactate 
release between two groups.  We recorded electrographic activity in CBM and modified 
media cultures from 10 DIV to 14 DIV (Figure 4.9B, C; for CBM, n = 13 cultures from 3 
animals; for modified medium, n = 14 cultures from 3 animals). No significant differences 
were observed in ictal activity incidence (p = 0.853, z-test). In cultures with seizures (n = 
7 cultures for CBM and modified medium), no significant differences were observed in the 
number of seizure per hour, average seizure duration or time seizing (p = 0.642, p = 0.937, 
p = 0.506 respectively, t test). It therefore appears that this modified medium was 
moderately neuroprotective (better morphology, lower LDH), but did not affect 
epileptogenesis.  
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Figure 4.9 Epileptogenesis occurs independently of medium composition. (A) Left: 
brightfield images at 14 DIV. Modified medium refers to the medium with lower 
concentrations of glycine and serine (0.01 mM) and higher concentration of magnesium 
(2.0 mM) compared to CBM. Scale bars, 500 µm; Right: time course of LDH and lactate 
concentration; n = 3 cultures, each condition. Error bars indicate SD. *p < 0.05. (B) 
Representative recordings of electrographic seizure-like events in organotypic cultures 
maintained in CBM and modified medium on 11 DIV. Seizure detail is shown in lower 
traces. Red lines indicate the threshold for paroxysmal event detection. (C) Comparison of 
electrographic seizures in cultures maintained in CBM or modified medium during 10-14 
DIV. n = 13 cultures for CBM; n = 14 cultures for modified medium; only cultures with 
seizures used for quantification of seizure frequency, duration, and time seizing. Error bars 
represent 95% confidence intervals for incidence of ictal activity and SD for other graphs. 
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4.4 Discussion 
4.4.1 Interpretation of morphology, lactate, and LDH data 
 
Slice dissection results in substantial cell death at the surface layers of hippocampal slices.  
Cell death in organotypic hippocampal cultures continues until 3 DIV, and then almost 
completely disappears by 7 DIV as dead cells are cleared from organotypic cultures 
maintained in serum-based or Neurobasal-A/B27 media [19].  Brightfield microscope 
images taken at 3 DIV show relatively dark but clearly distinguishable neural layers, while 
images taken at 7 DIV show much brighter neural layers.  Measurement of LDH in the 
culture medium at 3 DIV (capturing LDH release between 0 and 3 DIV) reveals much 
higher LDH concentration (corresponding to higher cell death [40]) than at 7 DIV (LDH 
release between 3 and 7 DIV) [19].   From 7 to 14 DIV, the incidence of spontaneous 
electrographic seizures increases in organotypic hippocampal cultures maintained in 
serum-based or Neurobasal-A media [18,19].  Spontaneous seizures are accompanied by 
activity-dependent neuron death, which results in darker, less distinguishable neural layers 
by 10 – 14 DIV. The glutamate receptor antagonist kynurenic acid and anticonvulsant 
phenytoin reduce occurrence of spontaneous seizures and accompanying cell death.  
Cultures maintained in the presence of kynurenic acid or phenytoin have clearer neural 
layers and release less LDH into spent culture media  between 10 – 14 DIV than vehicle-
treated cultures [19,47]. Thus, in cultures maintained in serum-based or Neurobasal-A 
media, morphology and LDH release are closely linked, and follow a predictable pattern: 
darker cultures and high LDH release signifying high cell death between 0 and 3 DIV, 
brighter, clearer cultures, low LDH release, and low cell death, between 3 and 7 DIV, and 
darker cultures and increasing LDH release accompanying seizure-induced cell death after 
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7 DIV.  Lactate release into culture medium is correlated to the amount of time spent 
cultures seizing per hour [4].  Thus, little lactate is released into culture medium until 7 
DIV, while after 7 DIV, increasing incidence of seizures causes increasing lactate release. 
We found that changes in medium composition can negatively affect culture survival, and 
reduce the correlation between morphology and LDH release.  For example, exclusion of 
vitamins in culture medium did not affect LDH release, but caused significant changes in 
morphology (Figure 4.5F).  This may occur because LDH release from dead cells is 
affected by the mode of cell death: loss of membrane integrity in necrotic cells results in 
release of LDH into culture supernatant, while most of LDH in apoptotic cells may be 
degraded without release into extracellular space [39].  Therefore, we used culture 
morphology as first determinant of culture survival in different media, while LDH release 
was used to gauge culture survival when no differences were detected morphologically. 
When a change in medium composition resulted in decreased culture survival, lactate 
release was also decreased (effects of 0.01x insulin in Figure 4.3C or 4 mM Ca2+ in Figure 
4.7B).  This decrease occurred due to fewer surviving cells present in the culture to release 
lactate, and not necessarily due to lower seizure load.  Thus, lactate, LDH, and morphology 
data needed to be analyzed together to determine effects of a medium composition on 
culture survival and development of epilepsy. 
4.4.2 Effect of medium composition on epileptogenesis 
 
We investigated the influence of BSA, selenium and insulin on culture survival. Albumin 
may play a role in epileptogenesis by triggering TGF-β pathway activation after blood-
brain barrier is compromised [34,48]. However, we did not observe any significant 
differences in morphology, LDH or lactate in cultures maintained in various concentrations 
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of BSA. Selenium is an antioxidant trace element that is protective against oxidative 
damage and can prevent the development of epilepsy induced by peroxidative injury [49–
51]. Our experiments confirmed that selenium is essential to culture survival, but 
increasing the concentration of selenium had no beneficial or harmful effects. Insulin is 
frequently used in serum-free media formulations to stimulate cell growth [52], and has 
been reported to prevent apoptosis of external granular layer neurons in rat cerebellar slice 
cultures [53]. Our experiments confirmed that insulin affects neuronal size and is essential 
for neuronal survival (Figure 4.4). We therefore supplemented all media used in subsequent 
experiments with insulin and selenium to promote neuronal survival, and with BSA 
concentration that was in the range of albumin concentration in normal CSF.  
We attempted to change concentrations of essential and non-essential amino acids, 
vitamins, electrolytes, and glucose to bring culture medium composition closer to CSF 
composition.  We found that changing concentrations of essential amino acids, or removing 
some essential amino acids, negatively affected culture survival. Similarly, we found that 
organotypic cultures could not survive without vitamins.  On the other hand, we found that 
cultures were more tolerant of changes in concentrations of non-essential amino acids, 
electrolytes, and glucose.  Alanine and proline could be removed from culture medium, 
while concentrations of glycine and serine could be varied from 10 to 400 µM without 
affecting culture viability.  We also found that concentration of glucose in the range of 11 
– 25 mM, [Ca2+] between 1 - 2 mM, [Mg2+] between 0.5 - 4 mM, and [K+] between 3.5 - 
8.5 mM supported culture survival.   
In healthy CSF, the concentration of K+ is 2.7 - 3.9 mM, the concentration of Mg2+ is 1 - 2 
mM and the concentration of Ca2+ is 1.5 – 2.5 mM [22,25,27].  Changes in the 
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concentrations of these ions can alter neuronal excitability and lead to spontaneous 
epileptiform activity [22,27,43,54–57].  Glucose concentration in CSF is approximately 
1.5 - 5 mM, although 10 – 11 mM concentrations are used in acute slice preparations to 
compensate for the altered glucose delivery pathway: rather than active transport from 
capillaries, glucose is provided via the diffusion gradient between the bathing medium and 
the extracellular fluid of actively metabolizing cells [27,46].  CSF contains 25 – 300 µM 
of serine and 5 – 40 µM of glycine depending on age [28,29,58].  Glycine affects excitatory 
neurotransmission by modulating N-methyl-d-aspartate (NMDA) receptor activation and 
desensitization [59–61], activates glycine receptors, and alters induced epileptiform 
activity [62].  L-serine (contained in culture medium) serves as a precursor for the synthesis 
of neuromodulators glycine and D-serine [63], which is also a co-agonist for the majority 
of NMDA receptor subtypes [61,64]. Finally, L-serine and glycine can act as trophic 
factors for survival and dendritogenesis of neurons [65].  
We created two CSF-based media, CBM and modified CBM, to examine whether 
epileptogenesis in organotypic cultures is caused by medium composition. Comparison 
between CBM and Neurobasal-A revealed that both media supported culture survival 
equally well, with a trend toward lower excitability in CBM cultures relative to 
Neurobasal-A cultures.  This may be due to lower [K+] and glucose in CBM.  However, 
the incidence of electrographic seizures was the same in both media, leading us to conclude 
that effect on epileptogenesis was minor. In modified CBM, we increased [Mg2+] to 2 mM , 
and reduced glycine and serine concentrations to 10 µM in an effort to minimize 
excitability but keep medium components within physiological ranges (note that Mg2+ was 
more protective at 4 mM, but this concentration is higher than what is found in CSF).  
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Reducing glycine concentrations from 400 µM to 10 µM, which is slightly below the point 
of saturation for NMDA receptors [66], and increasing [Mg2+] from 1.3 mM to 2 mM may 
reduce Ca2+ entry through the NMDA receptors during seizures, thus lowering 
excitotoxicity [67]. However, electrophysiological recordings revealed that there were no 
changes in seizure incidence or the total time seizing; in other words, epileptogenesis was 
not altered in cultures maintained in medium that was formulated for low excitability. On 
the other hand, culture survival was slightly improved. 
 
4.5 Conclusion 
Changes to culture medium composition moderately reduced electrographic seizure load 
and decreased cell death in organotypic hippocampal cultures.  However, epilepsy 
developed in all media compositions that supported neuronal survival.  Thus, medium 
composition is unlikely to be the cause of epileptogenesis in the organotypic hippocampal 
culture model of epilepsy. 
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Chapter 5 
Conclusion and future perspectives 
 
 
5.1 Conclusion 
The work presented in this thesis delivers solutions to the throughput limitation in in vitro 
antiepileptogenic drug discovery (Chapter 2, 3), and provides further validation of the 
organotypic culture based in vitro model of epilepsy (Chapter 4).  
In Chapter 2, we described a microfluidic perfused drop culture method to maintain 
organotypic cultures for over two weeks. This technique reduced the footprint required by 
brain slice cultures, and thus enabled the placement of a culture array on a single device, 
which dramatically improved the scalability.  
In Chapter 3, we presented a µflow-MEA technology for antiepileptogenic drug discovery. 
The integration of the microfluidic perfusion system with customized MEA allowed the 
maintenance of 6 cultures on a single 2 × 2 inch device for scalable chronic electrical assay 
of epileptogenesis. Field potential simulation confirmed that a simplified MEA design 
(with uninsulated electrodes) was able to achieve good detection of seizure-like activity. 
The in vitro model of epilepsy was validated on the µflow-MEA by neuron viability 
evaluation, epileptogenesis verification, and anticonvulsant test. A two-stage screening 
platform was developed to carry out a pilot screen of receptor tyrosine kinases (RTKs) 
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inhibitors. In stage I, several RTK inhibitors showed significant reducing effect in lactate 
dehydrogenase (LDH) and lactate levels. In stage II, our preliminary data of µflow-MEA 
based chronic electrophysiology confirmed the results of the stage I screen and identified 
the antiepileptogenic properties of cFMS RTK inhibitor. This work demonstrated the 
capability of µflow-MEA technology to facilitate high-throughput antiepileptogenic drug 
discovery. 
In Chapter 4, we further validated the organotypic hippocampal culture model of epilepsy 
by studying the influence of culture medium composition on epileptogenesis. We 
systematically studied the composition of the Neurobasal-A/B27 culture medium system 
and identified the essential components for culture survival. By excluding the non-essential 
components, we made a simplified medium for further study. We then altered the 
concentration of individual components and measured the effects on epileptogenesis and 
found that the modification of glycine, serine and Mg can moderately reduce ictal activity 
and that epileptogenesis occurred in all culture medium that supports neuronal survival. 
This study proved that epileptogenesis is independent of medium composition. 
It is hoped that the techniques presented in this thesis will accelerate antiepileptogenic drug 
discovery and contribute to the development of new therapeutics to treat individuals at risk 
of epileptogenesis.   
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5.2 Future perspectives 
5.2.1 Microwire based sequential recording platform for broad drug screening 
Our µflow-MEA technology provides continuous recording and enables the evaluation of 
drug efficacy at high-resolution. However, at this point, the throughput of this platform is 
limited by the number of channels in the data acquisition system we have in the lab, since 
a 16-channel workstation can support only 1 screen of 3 drugs per 2 weeks. To increase 
the experimental throughput, an upgraded multichannel workstation is required to support 
higher degree of parallelism. Besides the µflow-MEA system, we developed a new 
sequential recording platform based on the microwire electrode technique, so that multiple 
screen experiments can be performed at the same time with one 16-channel workstation.  
The microwire electrode array technique has been developed for decades and is a well-
established neural implant for in vivo study [1,2]. To our knowledge, this technique has 
not been utilized for chronic recordings in organotypic cultures. We cultured a 
hippocampal slice on a PFA-coated tungsten wire (bare diameter = 50.8 µm, coated 
diameter = 101.6 µm, A-M systems Inc.) that was affixed to the substrate of 6-well culture 
plate by PDMS, and we found that the existence of the microwire did not influence the 
culture survival (Figure 5.1A). We then built a microwire integrated culture plate for neural 
recording (Figure 5.1B). In each culture well, a recording electrode was fixed to the 
substrate with the microwire tip placed in the center, where the slice culture would be 
inserted, and a reference electrode (same type of microwire with 1.5 cm insulation layer 
removed at the tip) was placed on the side. Then organotypic cultures were maintained in 
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microwire plates for two weeks. Plates were transferred to a mini incubator (37 °C and 5% 
CO2) for one hour electrical recordings every other day (Figure 5.1C).  
To demonstrate the capability of microwire recording platform to screen drugs, we retested 
cFMS RTK inhibitor, which was previously identified as having a significant 
antiepileptogenic effect in the µflow-MEA based screen (Chapter 4), and Flt-3 RTK 
inhibitor, which did not show an obvious antiepileptogenic effect, as a negative control. 
We used four parameters to evaluate the drug efficacy: time seizing, tonic time (processing 
methods are described in section 5.2.2), average event rate, and electrographic load. 
Average event rate referred to the average paroxysmal event number (in 10 s time window) 
in one hour recording. Electrographic load was the integration of the power of voltage with 
time. The screen results agreed with our previous observation (Figure 5.1D-H) that cFMS 
inhibitor treated cultures showed significantly decreased time seizing and average event 
rate (p = 0.0214, p < 0.001, respectively, Kolmogorov–Smirnov test, n = 4 each condition, 
cultures from the same animal), and moderately decreased electrographic load (p = 0.056, 
Kolmogorov–Smirnov test). No significant drug effect was seen in the cultures treated with 
Flt-3 inhibitor. Representative recordings are shown in Figure 5.1H.    
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Figure 5.1 Microwire based sequential recording platform for drug screening. (A) 
Microwire electrode is compatible with organotypic culture. Scale bars, 500 µm. (B) The 
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electrode layout in a 6-well plate culture well. (C) Recording schedule for two weeks 
culturing. (D-H) Screen results of cFMS inhibitor and Flt-3 inhibitor. Drug efficacy was 
evaluated by time seizing per hour (D), tonic time per hour (E), average event rate (F), and 
electrographic load (G). (H) Representative recordings on 12 DIV. Histogram on the right 
shows the distribution of event rate in one hour recording. Kolmogorov–Smirnov test, n = 
4 each condition, cultures from the same animal. Error bars indicate SD.   
 
In this microwire recording setup, each screen experiment can test 2 drugs and 1 control 
with n = 4, and at most 6 screens can be conducted every 2 weeks, rendering a throughput 
of 24 drugs per month. Therefore, microwire recording platform provides higher 
experimental throughput, allowing for fast and broad screen of compound libraries. 
However, due to compromised recording resolution, it is important to subject the findings 
obtained in this platform to subsequent continuous monitoring. We expect the future 
applications of microwire based screen platform in rapid dissection of complex cell 
signaling pathways in epilepsy.   
5.2.2 Seizure type classification and transition study  
We developed an automated algorithm for seizure quantification and seizure type (refers 
to different tonic and clonic phase composition) classification. Two sets of analysis were 
performed: (1) bin duration was set as 0.5 s, aiming to identify event rates of up to 2 Hz 
(tonic-clonic phase of electrographic seizures); (2) bin duration was set as 0.1 s, intending 
to identify event rates of up to 10 Hz (tonic phase of electrographic seizures) [3–6] (Figure 
5.2A). 
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Figure 5.2 Drug effects on seizure type. (A) Tonic-clonic seizures and its tonic phase 
were quantified separately for seizure type study. (B-E) The influence of cFMS inhibitor 
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on seizure type. (B) one hour recordings with consistent seizure activity were selected for 
analysis. (C-D) Representative seizure type and its tonic composition in each condition. (E) 
Quantification of average seizure duration (left), average tonic phase duration (middle), 
and tonic phase percentage (right). *** p < 0.001, t-test, n = 32 seizures for control, and n 
= 14 seizures for cFMS-treated culture. Error bars indicate SD.     
 
Interestingly, we found that cFMS inhibitor significantly reduced the duration of tonic-
clonic seizures (Figure 5.1D), but it did not show obvious effects on the tonic phase of 
seizures (Figure 5.1E). Similar results were also observed in our chronic data. It might 
suggest that cFMS inhibitor modifies the seizure type by increasing the tonic phase 
duration in tonic-clonic seizures. To test this hypothesis, we quantified the duration of 
tonic-clonic seizures and the tonic phase duration in one hour recordings. We selected the 
recordings with consistently occurring seizure activity of a vehicle-treated control and a 
cFMS-treated culture for this analysis (Figure 5.2B). Treatment with the cFMS inhibitor 
did not change the duration of individual tonic-clonic seizure, but it significantly increased 
the  tonic phase duration in each seizure, thus increasing the tonic phase percentage (Figure 
5.2E, p = 0.181, <0.001, and <0.001, respectively, t-test, n = 32 seizures for control, and n 
= 14 seizures for cFMS inhibitor-treated culture). Representative plots presenting the 
seizure type modifications are shown in Figure 5.2C, D.  
To find the biological explanations of the drug effect on seizure type would be an 
interesting topic we can explore in future studies. Moreover, seizure type is variable over 
time. The dynamic of seizure type transition can be studied by analyzing chronic data with 
sufficient sample size, which might add to our understanding of the mechanism of epilepsy 
progression.     
 137 
 
Finally, we expect that future applications of our antiepileptogenic drug screening 
platforms will include experiments with libraries of peptides, antibodies, and silencing 
RNA that would achieve more specific inhibition of a broader range of potential drug 
targets. We also expect that this platform may have future applications in 
neurodevelopment research and drug discovery for psychiatric disorders.  
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